Stockwinners Market Radar for March 25, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:19 EDT Cathie Wood's ARK Investment bought 740K shares of Roblox today

20:17 EDT Cathie Wood's ARK Investment bought 129K shares of Twist Bioscience today

19:50 EDT ETAO International Co Ltd trading halted, news pending

18:03 EDT Bruush Oral Care receives additional delisting notification from Nasdaq - Bruush Oral Care announced that it has received a notice from the Listing Qualifications Department of The Nasdaq Stock Market on March 20, notifying the company that because the company is delinquent in filing its annual report on Form 20-F for the year ended October 31, 2023, this deficiency serves as an additional basis for delisting the company's securities from Nasdaq per Listing Rule 5810(d). This deficiency will be considered by the Hearings Panel at a hearing that has been scheduled for April 25 to address the company's other current deficiencies.

17:26 EDT Inari Medical to replace Callon Petroleum in S&P 600 at open on 4/1 - APA Corp. (APA) is acquiring Callon Petroleum (CPE) in a transaction expected to be completed on or about that date pending final conditions.

17:16 EDT Samsara's Lara Caimi sells over $722K in company shares - Officer of Samsara, Lara Caimi, disclosed the sale of 19,379 shares of company stock at $37.26 per share on March 21, for a total transaction amount of $722,007.

17:05 EDT Waldencast regains compliance with Nasdaq filing requirements - Waldencast plc received formal notice from the Nasdaq Hearings Panel confirming that it has regained compliance with Nasdaq's filing requirements, as set forth in Nasdaq Listing Rule 5250(c) following the filing of the company's financial results for the interim period ended June 30, 2023 with the U.S. Securities and Exchange Commission. In line with the applicable Nasdaq Listing Rules in such circumstances, the notice also indicated that Nasdaq had imposed a "Mandatory Panel Monitor" as that term is defined in Nasdaq Listing Rule 5815(d)(4)(B), for a period of one year from the date of the compliance determination, pursuant to which in the event the company fails to timely satisfy the Periodic Filing Rule during the one-year monitor period, the company will not have the opportunity to provide a compliance plan for the Nasdaq Listing Qualifications Staff's review; rather, Nasdaq would instead issue a delist determination pursuant to which the company could request a hearing and stay of the delist determination pending another hearing before the Panel.

16:46 EDT Webster Financial CFO MacInnes to retire - Webster Financial Corporation announced that after 13 years with the company, Glenn MacInnes intends to retire from his role as Executive Vice President and Chief Financial Officer. MacInnes will continue to serve as the company's CFO until a successor is appointed by Webster's Board of Directors and will then serve in an advisory role to ensure a smooth transition. "Glenn's contributions as CFO have helped transform Webster into one of the best-performing regional banks in the nation. During his tenure, Glenn spearheaded several initiatives aimed at improving profitability and operational efficiency. As a result, today Webster is on strong financial footing and is well-positioned for long-term value creation as we continue helping clients achieve their goals," said John Ciulla, Chairman and Chief Executive Officer of Webster Financial Corporation. "We have initiated a robust search process, looking at both external and internal candidates, to find Glenn's successor."

16:38 EDT Macy's VP Kirgan sells $308K in company shares - VP at Macy's Danielle Kirgan disclosed the sale of 15,070 shares of company stock at $20.42 per share on March 22, for a total transaction amount of $307,677.

16:32 EDT Beyond names Carlisha Robinson chief customer officer - Beyond announced the promotion of Carlisha Robinson to Chief Customer Officer, effective immediately. In her new role, she's responsible for all product management and user experience functions across the company, overseeing our customer file, enhancing our loyalty program, improving customer service, and launching Beyond+ product and service offerings. "Carlisha's intensity for the customer and vendor aligns with the tempo and tenor our company must have," said Marcus Lemonis, Executive Chairman of the Beyond, Inc. Board of Directors. The launch of Overstock.com this week, the launch of Zulily.com in late Q2, and other significant partnership and brand launches we're working on require the laser focus Carlisha brings to everything she touches."

16:32 EDT NYSE to commence delisting proceedings against Fisker - The New York Stock Exchange "announced that the staff of NYSE Regulation has determined to commence proceedings to delist the Class A common stock of Fisker Inc. from the NYSE. Trading in the Company's Class A common stock will be suspended immediately. NYSE Regulation has determined that the Company's Class A common stock is no longer suitable for listing based on "abnormally low" price levels, pursuant to Section 802.01D of the Listed Company Manual."

16:30 EDT Momentus names Lon Ensler interim CFO - Momentus said it welcomes new interim Chief Financial Officer Lon Ensler to the company. Ensler will assume the role of interim CFO on April 2, following the departure of the company's incumbent Chief Financial Officer, Eric Williams. Lon Ensler brings over 30 years of financial leadership and experience to Momentus. His diverse background spans both established corporations and dynamic startups, making him an excellent fit to enable the company's growth trajectory. Momentus CEO John Rood said, "We're thrilled to welcome Lon to our executive team. His wealth of experience at both large companies and tech startups are well suited to guide the company's growth. Lon has a strategic mindset, experience raising capital, mergers and acquisitions, and guiding financial planning and execution to enable growth."

16:21 EDT Core & Main to acquire EGW Utilities, terms not disclosed - Core & Main has entered into a definitive agreement to acquire substantially all of the assets of EGW Utilities, a distributor of quality products and services to underground utility contractors and municipalities, based in Texas. "With the acquisition of EGW, we are excited to expand our product offering and service capabilities in the underground utility industry," said Steve LeClair, chairman and CEO of Core & Main. "Their team brings a wealth of knowledge and technical expertise and will be a wonderful complement to our existing business in this area." Located in Carrollton, Texas, EGW has provided reliable underground utility infrastructure products and services since 2001. Their commitment to delivering exceptional solutions and maintaining strong customer relationships has enabled them to consistently provide their customers with the resources and support needed to complete their projects successfully.

16:18 EDT Golden Sun receives noncompliance letter from Nasdaq - Golden Sun announced the company received a staff determination letter from the Listing Qualifications Department of Nasdaq notifying the company that, due to the company's failure to regain compliance with a minimum bid price of $1.00 per share requirement for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550, the staff has determined that company's securities will be scheduled for delisting from Nasdaq unless the company requests an appeal of this determination to a hearings panel.

16:15 EDT Eventbrite names Julia Hartz executive chair - Eventbrite announced the appointment of CEO Julia Hartz to the role of Executive Chair of the Board of Directors, effective June 6, 2024. Additionally, current Executive Chairman Kevin Hartz will not stand for re-election to the board of directors at the annual general meeting on June 6, 2024, and current board member Steffan Tomlinson will step down from the board effective immediately. Kevin Hartz will complete his current term, and Julia Hartz will become the Executive Chair of Eventbrite while continuing to serve as CEO. Board member Sean Moriarty will remain Lead Independent Director. A serial entrepreneur, Kevin Hartz co-founded Eventbrite with his wife Julia Hartz, and Renaud Visage, in 2006. He served as Executive Chairman and CEO for ten years, after which he became the Executive Chairman of the Board of Directors in 2016. Kevin has also been a prolific angel investor in Silicon Valley over the last two decades, backing companies such as PayPal, Airbnb, Ramp, Anduril and Pinterest. He founded A*, an early-stage venture capital firm based in San Francisco in 2021, and is now launching their second fund with co-founders Gautam Gupta and Bennett Siegel. Kevin will continue to dedicate his time to investing in and launching companies on the A* platform. "Working with Julia and the Eventbrite team has been an incredible honor and privilege. I'm confident that the company remains in great hands with steadfast leadership. I'm proud of what we have accomplished so far, serving millions of event creators and hundreds of millions of consumers worldwide," said Kevin Hartz.

16:13 EDT Sonoco Products increases price for uncoated recycled paperboard in Europe - Sonoco announced it is implementing a EUR 60 per ton, GBP 50 for UK market, price increase for all grades of uncoated recycled paperboard, or URB, sold in Europe effective for deliveries after April 15.

16:06 EDT Poseida Therapeutics names Syed Rizvi, M.D., as Chief Medical Officer - Poseida Therapeutics announced the appointment of Syed Rizvi, M.D., as Chief Medical Officer effective April 1. Dr. Rizvi is a seasoned executive with over 20 years of experience across all stages of drug development, including clinical strategy, execution, and commercialization. Dr. Rizvi most recently served as Chief Medical Officer of Caribou Biosciences, where he was responsible for overall strategy and execution of all clinical development programs.

16:02 EDT Stoke Therapeutics announces new data from STK-001 studies - Stoke Therapeutics announced landmark new data from two open-label Phase 1/2a studies and two open-label extension studies of children and adolescents ages 2 to 18 with Dravet syndrome who were treated with STK-001. Data from these studies showed clinically meaningful effects, including substantial and durable reductions in convulsive seizure frequency and improvements in multiple measures of cognition and behavior that support the potential for disease modification. These improvements were observed among a highly refractory group of patients who were already taking the best available anti-seizure medicines. STK-001 has been generally well-tolerated in studies to date. Today, the Company also announced clearance from the U.S. Food and Drug Administration that allows patients to receive three doses of 70mg followed by continued dosing at 45mg. Based on this regulatory update and these data, the Company plans to meet with regulatory agencies to discuss a registrational study that includes initial doses of 70mg followed by continued dosing at 45mg. "The totality of these data provide compelling evidence that support the potential for STK-001 to be a disease-modifying medicine for patients with Dravet syndrome by treating the underlying cause of the disease, rather than just the symptoms," said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. "STK-001 is the first medicine in development to demonstrate substantial and durable reductions in seizure frequency and improvements in multiple measures of cognition and behavior. These effects were observed in patients who were already taking the best available anti-seizure medicines, which confirms our highly differentiated mechanism of action and approach to treating this disease. We look forward to meeting with regulatory agencies to discuss our plans for a randomized, controlled registrational study and to providing an update coming out of those discussions later in 2024."

13:44 EDT Citi says final phase of organizational simplification concluded - Citi issued the following statement on the final phase of organizational simplification changes: "Today we shared with our colleagues that we have concluded the major actions that we announced in September 2023 that align Citi's structure with our simplified operating model. While these decisions were not made easily, they have allowed us to strengthen how we run the bank and serve clients through enhanced connectivity and accountability. After having reset Citi's strategy and undergone these consequential changes, we will continue to execute on our vision to be the preeminent banking partner for institutions with cross-border needs, a global leader in wealth and a valued personal bank in our home market and focus on our commitment to transform the company for the long term." Reference Link

12:05 EDT Dow Inc. to invest in carbonate solvents facility in the U.S. - Dow announced the intent to invest in ethylene derivatives capacity on the U.S. Gulf Coast, including the production of carbonate solvents, critical components to the supply chain of lithium-ion batteries. This investment supports growth in domestic electric vehicle and energy storage markets and builds on Dow's successful track record of growth projects, including the recent global alkoxylation capacity expansions expected to come online in the next two years in U.S. Gulf Coast and Europe. Dow is collaborating with the U.S. Department of Energy Office of Clean Energy Demonstrations and was selected for award negotiations to establish a world-scale carbonate solvents production facility for lithium-ion battery production on the U.S. Gulf Coast. The project is supported by agreements with customers, including leading EV original equipment manufacturers and electrolyte manufacturers. This facility will capture more than 90% of the carbon dioxide from the ethylene oxide manufacturing process and will utilize it to produce carbonate solvents needed for the electrification of vehicles and to strengthen the U.S. power grid through energy storage. This investment is in line with Dow and the U.S. government's goals to enable reduction of greenhouse gas emissions in the mobility and transportation sector by investing in supply chain resiliency for domestic battery and EV manufacturing.

12:00 EDT Alto Neuroscience rises 10.8% - Alto Neuroscience is up 10.8%, or $1.72 to $17.69.

12:00 EDT ReposiTrak falls -9.4% - ReposiTrak is down -9.4%, or -$1.61 to $15.54.

12:00 EDT Compass Minerals falls -14.9% - Compass Minerals is down -14.9%, or -$2.62 to $14.94.

11:42 EDT Digital World Acquisition, Trump Media complete business combination - Digital World Acquisition Corp. (DWAC) and Trump Media & Technology Group, or "TMTG," announced the completion of their business combination. Digital World now operates as "Trump Media & Technology Group Corp." following the successful completion of the business combination. Beginning on Tuesday, March 26, the common stock and public warrants of TMTG are expected to begin trading on the Nasdaq Stock Market under the ticker symbols "DJT" and "DJTWW," respectively. TMTG, as a publicly traded company, will continue to be led by Chief Executive Officer, Devin Nunes, and its existing management team. "As a public company, we will passionately pursue our vision to build a movement to reclaim the Internet from Big Tech censors. We will continue to fulfill our commitment to Americans to serve as a safe harbor for free expression and to stand up to the ever-growing army of speech suppressors. As we mark this milestone, I want to particularly thank Eric Swider for his unflagging dedication to our deal and our cause," said TMTG CEO Devin Nunes.

10:58 EDT Curo Group enters RSA, commences voluntary Chapter II reorganization - CURO Group Holdings announced that, on March 22, 2024, it entered into a Restructuring Support Agreement that is supported by holders of more than 74% of each of: loans under the Company's First Lien Credit Agreement, the Company's 7.500% Senior 1.5 Lien Secured Notes due 2028 and the Company's 7.500% Senior Secured Notes due 2028. To implement the terms of the RSA, CURO and certain subsidiaries have filed for voluntary relief under Chapter 11 of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of Texas, Houston Division. Prior to commencing the Chapter 11 Cases, the Company also commenced solicitation of the 1L Lenders, the 1.5L Noteholders, the 2L Noteholders and holders of CURO's common stock for votes for a prepackaged joint plan of reorganization of the Company and certain of its subsidiaries, which Plan has been filed contemporaneously with the filing of the Chapter 11 Cases. CURO also intends to file recognition proceedings in Canada under Part IV of the Companies' Creditors Arrangement Act. The RSA sets forth terms for a consensual restructuring plan that is expected to reduce the Company's debt by approximately $1 billion, saving the Company approximately $75 million in cash interest annually and enabling CURO to invest in long-term growth. CURO branches are open, operating as usual and continuing to serve customers in the U.S. and Canada. Customer loans are unaffected by the filing. A steering committee comprised of funds managed by Oaktree Capital Management, Caspian Capital LP, and Empyrean Capital Partners led negotiation of the RSA on behalf of creditors. CURO has filed a number of customary motions with the Bankruptcy Court to ensure that its operations continue uninterrupted while its balance sheet is restructured. CURO has also received a commitment of up to $70 million of new capital in the form of debtor-in-possession financing from certain of the Company's prepetition stakeholders, subject to satisfaction of certain customary conditions. The DIP financing, which is subject to court approval, is expected to support the Company's ongoing operations during the court-supervised process. Given the broad support of lenders, CURO expects to receive Bankruptcy Court approval of a Plan of Reorganization and Disclosure Statement expeditiously and it expects to emerge from the restructuring process in no later than 120 days. In connection with the Chapter 11 Cases, the applicable non-debtor subsidiaries of the Company also entered into waivers and amendments with the lenders under the Company's existing loan receivables securitization programs. These accommodations ensure that such securitization programs remain in effect notwithstanding the filing of the Chapter 11 Cases and are able to continue, with certain negotiated modifications, following the Company's emergence from Chapter 11.

10:36 EDT Moleculin Biotech trading halted, volatility trading pause

10:33 EDT Take-Two falls after Kotaku says after GTA 6 could miss release window - Shares of Take-Two Interactive after sources told gaming website Kotaku that Grand Theft Auto VI could miss its 2025 release window and slip into 2026. Remote workers are struggling with an unwanted return-to-office mandate from Rockstar Games, sources told the website, Zack Zwiezen reported late Friday. It is becoming more and more likely that the sequel might not land until late 2025 and it is also possible that it could even slip into 2026 as production reportedly falls behind, according to Kotaku. Shares of Take-Two are down 6% to $143.56 in morning trading. Reference Link

10:18 EDT SAB Biotherapeutics enters partnership with Naval Medical Research Center - SAB Biotherapeutics announced that the Navy Medical Research Command is moving forward with a safety and tolerability study to evaluate SAB-176, a therapy being investigated for use as a pre- and post-exposure prophylactic treatment for influenza type A and type B, pursuant to the Cooperative Research and Development Agreement that governs the relationship between SAB and the NMRC. With funding for research provided by the Henry Jackson Foundation, this partnership will move forward a pharmacokinetic , safety and tolerability study designed as a double-blinded, randomized study with intramuscular SAB-176 administered to healthy volunteers. The NMRC Clinical Trials Center, located in Bethesda, Maryland, will be conducting this PK study under the leadership of Cmdr. Nehkonti Adams, Director, NMRC Clinical Trials Center.

10:03 EDT Deere names Kellye Walker as SVP, chief legal officer & worldwide public affairs - Deere & Company (DE) announced that former Eastman Chemical (EMN) executive, Kellye Walker, will join its leadership team as senior vice president, chief legal officer and worldwide public affairs, effective April 29. In her new role, Walker will succeed Mary Jones as the company's general counsel and have executive management responsibility for the global law and patent departments, as well as oversight of the company's public affairs and environmental, health, and safety functions. "Over the course of her career, Kellye has compiled an impressive record of experience and achievement," said John May, chairman & CEO of Deere & Company. "Her exceptional strategic leadership and problem-solving skills, along with her proven ability to deliver results in a rapidly changing environment, will be of real benefit to our company as we continue to deliver groundbreaking products, services, and outcomes for our ag, construction, and forestry customers around the world."

10:01 EDT O-I Glass selected by DOE to receive $125M investment for IDP funding - O-I Glass, Inc. was selected by the U.S. Department of Energy Office of Clean Energy Demonstrations to begin award negotiations for up to $125M in Bipartisan Infrastructure Law and Inflation Reduction Act funding as part of the Industrial Demonstrations Program. The O-I decarbonization project was selected as one of 33 projects across more than 20 states to receive up to a total of $6B to demonstrate commercial-scale decarbonization solutions needed to move energy-intensive industries toward net-zero while strengthening local economies, creating, and maintaining high-quality jobs, and slashing harmful emissions that jeopardize public health. The Glass Furnace Decarbonization Technology project, led by O-I Glass, plans to rebuild four furnaces across three of its facilities in California, Ohio, and Virginia to reduce scope 1 carbon dioxide emissions by an estimated 48,000 metric tons per year, an average of 40% reduction of scope one emissions across the four furnaces and their corresponding production lines.

10:00 EDT GameStop rises 10.8% - GameStop is up 10.8%, or $1.42 to $14.52.

10:00 EDT Biotie Therapies falls -5.1% - Biotie Therapies is down -5.1%, or -42c to $7.86.

10:00 EDT Compass Minerals falls -9.9% - Compass Minerals is down -9.9%, or -$1.73 to $15.82.

09:47 EDT Compass Minerals falls -6.9% - Compass Minerals is down -6.9%, or -$1.21 to $16.34.

09:47 EDT Foot Locker rises 7.0% - Foot Locker is up 7.0%, or $1.71 to $26.10.

09:47 EDT Forge Global rises 38.4% - Forge Global is up 38.4%, or 90c to $3.23.

09:38 EDT Flyexclusive Inc trading resumes

09:35 EDT Fisker trading halted, news pending

09:33 EDT Flyexclusive Inc trading halted, volatility trading pause

09:31 EDT Zentek announces preclinical safety, toxicity results for C19HBA - Zentek announces that its wholly-owned subsidiary Triera Biosciences has completed testing demonstrating that its C19HBA SARS-CoV-2 universal aptamer built on the proprietary high-binding affinity aptamer platform has shown a promising safety and toxicity profile in preclinical testing. This is a critical step in the path towards the development of a human therapeutic. Previously, the Company reported successful efficacy when C19HBA was tested as a prophylaxis and as a therapeutic. In repeated trials against SARS-CoV-2 variants, C19HBA has matched or exceeded the clinical protection compared to a leading monoclonal antibody. In a trial completed in February 2024 by the Miller lab at McMaster University, the safety and toxicity of C19HBA was assessed through a study that administered 258 microM of C19HBA intranasally to one cohort of mice with a similar-sized cohort receiving sham treatment. After two hours, half the mice from each cohort were sacrificed while the remaining mice were infected with a lethal challenge of the ancestral variant of SARS-CoV-2. After 24 hours all infected mice were sacrificed, and serum and BAL fluid samples were collected. These samples were analyzed for inflammatory cell infiltration and full cytokine panel. The inflammatory cell infiltration study demonstrated that mice treated with C19HBA had similar levels of macrophages, neutrophils, and monocytes as the naive mice both at the two-hour mark after C19HBA administration and 24 hours after infection. The cytokine panel analyzed 44 different biomarkers from the Bronchoalveolar Lavage BAL fluid of sacrificed mice. The major cytokine markers, VEGF-A and TNFalpha were consistent between naive mice and those treated with C19HBA.

09:29 EDT Vivakor to acquire Endeavor entities for $120M - Vivakor announced that as of March 21, 2024, it signed a definitive Membership Interest Purchase Agreement to acquire Endeavor Crude, LLC, Meridian Equipment Leasing, LLC, including its subsidiary CPE MidCon, LLC, Equipment Transport, LLC., and Silver Fuels Processing, LLC , collectively the Endeavor Entities from Jorgan Development, LLC and JBAH Holdings. Jorgan is an affiliate of James Ballengee, Vivakor's CEO. The Endeavor Entities operate in the midstream segment of the oil industry, which targets oil logistics, gathering and storage, including crude oil and produced water trucking and disposal services, and also operate a crude oil pipeline gathering system and pipeline injection stations. Vivakor expects to benefit from the expected synergies these acquisitions will create. In addition, each of the material businesses have 10-year take or pay contracts with White Claw Crude, LLC, an affiliate of Jorgan, which began on January 1, 2024, that provide minimum revenue levels. In the crude oil and produced water trucking business, the Endeavor Crude, LLC contract with White Claw Crude, LLC guarantees a volume of 75,000 barrels of crude oil be transported each day. The pipeline gathering contract with CPE MidCon, LLC guarantees a minimum pipeline throughput revenue of $200,000 per month. For the to be acquired Silver Fuels Processing injection stations, minimum contract guarantees call for 200,000 barrels per month of throughput at $0.275 per barrel. Additionally, SFP is in the process of constructing a new station located in the Permian Basin that is expected to add an additional 30,000 barrels per month for a new minimum of 230,000 barrels per month. Under the terms of the MIPA, unanimously approved by the board of directors of each party, during which vote, James Ballengee recused himself from voting in his capacity as Chairman of the Board of Vivakor, upon a successful closing, Vivakor would acquire 100% of the Endeavor Entities for $120 million, consisting of shares of Vivakor common stock to be valued at an above market price of $1.00 per share, in an amount to not exceed 19.99% of the total number of Vivkaor's pre-transaction issued and outstanding shares of common stock and shall not result in, taking into consideration common stock presently owned by Jorgan or its related parties, owning in excess of 49.99% of the common stock issued and outstanding on a post-closing basis; and shares of non-voting, 6% cumulative, Series A convertible preferred stock. Additional contingent consideration of up to $49 million, payable in Vivakor Series A convertible preferred stock, will be payable to Jorgan in the event the Endeavor Entities generate 2024 EBITDA in an amount greater than $12 million. Conversely, in the event the Endeavor Entities fail to generate a minimum of $12 million in 2024 EBITDA, up to $49 million of the purchase price consideration paid in the form of Series A convertible preferred stock will be subject to return by Jorgan to Vivakor for cancellation. The closing of the acquisition, is subject to, among other things completion of due diligence satisfactory to the parties, delivery of audited financials for the periods ended December 31, 2022 and 2023 for the Endeavor Entities, Vivakor's receipt of a satisfactory fairness opinion to the underlying transaction, approval under the Hart Scott Rodino Act, and other customary closing conditions. Vivakor is currently targeting the Acquisition to close by the end of the fiscal quarter ending June 30, 2024.

09:27 EDT PetroChina to step up efforts to promote oil and gas exploration, development - The company said, "Looking ahead to 2024, the Company will adhere to the five development strategies of innovation, resources, market, internationalization, and green & low-carbon development. With continuous efforts to strengthen production and operation, it will further promote high-quality and efficient development, safeguard the safe, stable and profitable operation of the oil and gas business. The Company will step up efforts to promote oil and gas exploration and development, strive to ramp up reserves and output to lay a solid foundation for growth. In addition, it will proactively adapt to energy transition and the changes in market demand, advance green and low-carbon transition in a steady manner and optimize the business layout, and accelerate the development of new energies and new materials. By reinforcing its sustainable development capability, the Company will continue to create value for shareholders and the community."

09:23 EDT Lexicon announces presentations of clinical data on sotagliflozin - Lexicon Pharmaceuticals nnounced that four data presentations related to sotagliflozin, an inhibitor of two sodium glucose transport proteins, will be delivered during the American College of Cardiology 73rd Annual Scientific Session & Expo being held April 6 - 8, 2024 in Atlanta, Georgia, including results from a post-hoc evaluation of the efficacy of sotagliflozin in reducing stroke events in patients with type 2 diabetes, chronic kidney disease, and high cardiovascular risk in the SCORED Phase 3 clinical trial. Details of the presentations are as follows: Sotagliflozin Reduces Stroke Outcomes in Patients with Diabetes and Chronic Kidney Disease - a moderated poster presentation, Monday, April 8, 12:15 - 12:25 p.m. ET, Theater 8 presented by Rahul Aggarwal, M.D., Icahn School of Medicine at Mount Sinai, New York, New York: Study researchers evaluated the efficacy of sotagliflozin in reducing all-cause and cause-specific stroke outcomes among patients with type 2 diabetes, CKD, and high CV risk. In a post-hoc analysis of data from the 10,584 patients in the SCORED Phase 3 clinical trial, 213 all-cause stroke events occurred, including 29 fatal events. Sotagliflozin reduced the risk of all-cause stroke by 34%, with 1.2 events per 100 patient-years in the sotagliflozin group and 1.8 events per 100 patient-years in the placebo group. Similarly, sotagliflozin reduced the risk of ischemic stroke by 32%, with 0.8 events per 100 patient-years in the sotagliflozin group and 1.2 events per 100 patient-years in the placebo group. Sotagliflozin, a Dual SGLT 1 and 2 Inhibitor, Modulated Expression of Glucose Transport and Inflammatory Proteins in Endothelial Cells following Angiotensin II Stimulation - a poster presentation, Sunday, April 7, 1:15 - 2:00 p.m. ET, 1425-157, Hall B4-5, presented by Preston Mason, Ph.D. MBA, Elucida Research, Beverly, Massachusetts: Study researchers found that sotagliflozin modulated expression of proteins linked to the Akt signaling pathway, glucose transport and vasodilation in human endothelial cells exposed to an inflammatory stimulus in vitro. The favorable endothelial cell actions of sotagliflozin during inflammation add to the body of knowledge of sotagliflozin's mechanism of action and are consistent with the reduced atherothrombotic risk demonstrated in outcome trials. Sotagliflozin, a First-in-Class SGLT1/2 Inhibitor, Inhibits Clotting Potential in the Vessel via Inhibition of Platelet Activation, Integrin Activation, and Aggregation in Human Platelets - a moderated poster presentation, Sunday, April 7, 11:30 - 2:40 a.m. ET, Theater 5 presented by Livia Stanger, Ph.D. Candidate, University of Michigan, Ann Arbor, Michigan: Study researchers found that sotagliflozin inhibits platelet activation through simultaneously targeting SGLT1 and SGLT2. These findings provide insight into the potential mechanism by which sotagliflozin impacts stroke and MI risk in patients with type 2 diabetes and CKD and provides a basis for further studies to explore the role of sotagliflozin for CV protection in patients at increased risk for ischemic events. Temporal Shift in Heart Failure Medications Prescribed to Hospitalized Patients According to Sex and Age. Results from Two Large US Integrated Health Systems - a poster presentation, Sunday, April 7, 9:15 - 10:00 a.m. ET, 1343-121, Hall B4-5, presented by Mario Enrico Canonico, M.D., Ph.D., CPC Clinical Research, University of Colorado, Aurora, Colorado: Study researchers found that substantial opportunity exists to further improve the prescription of guideline-directed medical therapy for patients with HF. Differences in timing of initiation of these therapies by sex and age highlight the need to evaluate care gaps by these and other determinants of health.

09:21 EDT Cassava Sciences says DSMB recommends Phase 3 trials continue as planned - Cassava Sciences announced the completion of another interim safety review of simufilam in on-going Phase 3 clinical trials in patients with Alzheimer's disease. A routine, scheduled meeting of a Data and Safety Monitoring Board recommended that both of Cassava Sciences' on-going Phase 3 studies continue as planned, without modification. The DSMB is composed of independent clinical research experts who periodically review interim patient safety data for Cassava Sciences' on-going Phase 3 trials of simufilam in Alzheimer's disease. This DSMB only reviews patient safety. It does not assess drug efficacy.

09:19 EDT Atlantica Sustainable Infrastructure acquires two wind assets in the UK - Atlantica Sustainable Infrastructure completed the acquisition of a 100% equity interest stake in two wind assets, with a combined installed capacity of 32 MW in Scotland, United Kingdom. The assets are regulated under the UK green attribute regulation and are granted renewables obligation certificates until 2033. They have demonstrated a solid operating track record and currently do not have any project debt. The acquisition closed on March 22, 2024, and Atlantica's investment amount was approximately $66 million. The purchase price represents an Enterprise Value1/EBITDA2 multiple of approximately 6.6 times. These are Atlantica's first operating assets in the U.K., and the Company expects that its return from these assets will be enhanced by the use of Atlantica's existing net operating loss carryforwards in the UK in the upcoming years.

09:18 EDT AIM ImmunoTech announces publication of findings from Ampligen study - AIM ImmunoTech announced the publication of new data analysis from a long-term Early Access Program studying the company's drug Ampligen for the treatment of advanced pancreatic ductal adenocarcinoma. The manuscript titled "Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses," appears in the journal Clinical Cancer Research, one of oncology's most prestigious journals. Ampligen is a dsRNA product candidate that acts via the TLR-3 receptor present on several immune cells, epithelial cells and tumors. Researchers at the Erasmus University Medical Center found that Ampligen treatment in pancreatic cancer patients enhances peripheral immune activity at the transcriptomic and proteomic levels, particularly involving type 1 conventional dendritic cells and T cells. Post-Ampligen, the increased peripheral abundance of BTLA+XCR1+ cDC1s and CD4+SELL+ T cells correlated with improved clinical outcomes. Patients with stable disease exhibited pronounced overexpression of genes related to DC and T cell activation. Notably, the expression of immune checkpoints PD-L1 and PD-L2 decreased post-Ampligen across all patients. AIM Chief Executive Officer Thomas K. Equels stated: "We have already seen that Ampligen as a single-agent therapy was associated with improved progression-free survival and overall survival in these Early Access Program pancreatic cancer patients. This new data analysis provides us further insight into exactly why that's the case, which could give us the ability to identify cancer patients who might benefit more from Ampligen treatment than they would from other known cancer treatments. Additionally, the changes in the tumor microenvironment we see in pancreatic cancer are similar to those we have seen in triple-negative breast cancer, ovarian cancer and colorectal cancer metastatic to the liver. We have hypothesized that Ampligen has the potential to be efficacious in almost every solid tumor type based on its direct effect on malignant tumor cells and its effect on the tumor micro-environment. All these data combined lend further credence to the broad applicability of Ampligen in solid tumors."

09:16 EDT Lucid Group up 15% at $3.19 after announcing $1B investment from PIF affiliate

09:15 EDT Coherent establishes capability for 6-inch InP wafer fabrication - Coherent Corp. has established the world's first capability for 6-inch indium phosphide (InP) wafer fabrication, in the company's Sherman, Texas, and Jarfalla, Sweden, wafer fabs. This exciting milestone enables Coherent to increase production capacity and lower die costs for InP optoelectronic devices, widely used in applications such as coherent optical communications, datacom transceivers, AI interconnects, advanced sensing for consumer electronics and wearables, medical and automotive applications, and, in the future, in 6G wireless and satellite communications networks.

09:10 EDT Essex acquires JV partner's 49.9% interest in BEXAEW portfolio for $505M - Essex Property Trust announced that it acquired its joint venture partner's 49.9% interest in the BEXAEW portfolio for a total purchase price of $505M on a gross basis. The seller's cap rate is approximately 5.25%; however, after incorporating additional economic benefits by fully integrating this portfolio into our operating platform, we estimate a 5.9% year-one yield. Concurrent with closing, the Company repaid $219.9 million of debt encumbering the properties and consolidated the communities on the Company's financials. The portfolio is comprised of four properties totaling 1,480 apartment homes. The portfolio generated an 11.4% IRR and the Company will recognize approximately $1.5M promote income, which will be excluded from Core FFO.

09:09 EDT Eastman Chemical selected by U.S. DOE to receive up to $375M investment - Eastman announced significant progress towards its leadership in the circular economy: Selected by the Department of Energy, DOE, as one of 33 companies for award negotiations to support Eastman's second U.S. molecular recycling facility; Named Longview, Texas, as the location for its facility; Finalized incentives with the State of Texas to assist with project funding. "We are excited to build our second U.S. world-scale molecular recycling facility at our existing site in Texas," said Mark Costa, Eastman Board Chair and CEO. "We have decades of history successfully operating in Longview, and this will be a great investment for the local community." Eastman's second U.S. molecular recycling project has been selected by the Department of Energy to begin award negotiations for up to $375 million in Bipartisan Infrastructure Law and Inflation Reduction Act funding as part of the Industrial Demonstrations Program. The DOE announcement led to Eastman announcing the intent to build a second U.S. molecular recycling facility at its location in Longview, Texas.

09:07 EDT Suburban Propane partners with Crayons to Classrooms - Suburban Propane Partners partnered with Crayons to Classrooms to support the organization's "Classroom Solutions" program, which provides local teachers with educational materials that add depth and value to their lesson plans and classroom displays.

09:07 EDT Fisker discloses notice of automaker terminating transaction talks - In a regulatory 8-K filing, the company states: "After the market closed on March 22, 2024, Fisker received notice from the large automaker with which the Company had been in negotiations for a potential transaction that the automaker terminated the negotiations. Following such termination, the Company continues to evaluate strategic alternatives. Such alternatives may include in or out of court restructurings, capital markets transactions, repurchases, redemptions, exchanges or other refinancings of its existing debt, the potential issuance of equity securities, the potential sale of assets and businesses and/or other strategic transactions and/or other measures. These alternatives involve significant uncertainties, potential significant delays, costs and other risks, and there can be no assurance that any of these alternatives will be available on acceptable terms, or at all, in the current market environment or in the foreseeable future. As a result of the termination of discussions with the automaker, the Company will not be able to meet a closing condition to the financing commitment and term sheet the Company entered into with an investor on March 18, 2024. As a result of the inability to meet such closing condition, the Company intends to engage in discussions with the Investor regarding a waiver of such closing condition. These alternatives involve significant uncertainties, and there can be no assurance that any of these discussions will be successful or that any funds will be available to the Company under the Commitment."

09:06 EDT TaskUs and V7 announce strategic partnership to enable AI product delivery - TaskUs and V7 are combining their expertise in AI and data annotation to optimize training data creation for AI product development at some of the world's biggest technology companies. With a proven track record in supporting enterprise retail, healthcare, and asset management industries, the collaboration between V7 and TaskUs offers customers accelerated training data delivery, reduced production costs, and turnkey enterprise solutions. The partnership aims to slash development cycles and enable enterprises to launch AI products significantly faster. The integration of TaskUs' teams of expert annotators, adeptly trained on V7's latest AutoML stack for swift annotation and iteration looks to achieve rapid progression on all projects in a true human-in-the-loop approach. TaskUs is training its teams of subject matter experts to accelerate training data delivery using V7's model-assisted labeling stack. This approach minimizes the ramp-up time for a customer's engineers, consequently mitigating the costs associated with wasted data production- a common cause of spiraling AI budgets.

09:05 EDT Gabelli Global Multimedia appoints Susan Watson Laughlin to board of trustees - The Board of Directors of The Gabelli Multimedia Trust announced the appointment of Susan Watson Laughlin to the Board of the Fund effective February 13, 2024. Most recently, she served in the Board of Directors Practice at Spencer Stuart.

09:05 EDT AudioCodes, TTBS collaborate to deliver voice calling for Microsoft Teams - AudioCodes announced a strategic collaboration with Tata Tele Business Services, TTBS. As a result of this collaboration, TTBS will use AudioCodes Live Platform for Microsoft Teams (MSFT) to offer Smartflo UCaaS, a voice solution integrated with Microsoft Teams, to their enterprise customers in India. AudioCodes Live Platform, a white label, multi-tenant SaaS solution, enables TTBS to streamline the delivery of Smartflo UCaaS on Microsoft Teams via Direct Routing and Operator Connect voice connectivity from a single platform integrated into their existing core network. "We are delighted to join forces with Tata Tele Business Services to enable Microsoft Teams Phone connectivity for their customers in India," said Lior Aldema, Chief Business Officer at AudioCodes. "Our innovative AudioCodes Live Platform and Voca solutions are designed to simplify and accelerate the adoption of Microsoft Teams as a unified communications, collaboration and contact center platform, while offering a superior user and customer experience that provides exceptional business value."

09:03 EDT Marvell announces Marvell Nova 2 - Marvell Technology announced Marvell Nova 2, the industry's first 1.6 Tbps PAM4 optical DSP featuring 200 Gbps electrical and optical interfaces to meet the escalating performance demands of accelerated infrastructure, generative AI, and high-performance computing. "200 Gbps signaling will be a defining feature for the next wave of AI clusters and cloud data centers and provide the performance needed to deliver services based on generative AI and large language models," said Xi Wang, Ph.D., vice president of product marketing for Optical Connectivity at Marvell. "The latest advancements in our Nova product family extend our longstanding leadership in PAM4 optical DSP technology to advance the industry towards next-generation cloud data center architectures."

09:01 EDT BioElectronics announces publication of canine arthritis study - BioElectronics announces the results and publication of a study investigating the efficacy of its FDA-cleared pulsed-shortwave-therapy device in initiating a systemic anti-inflammatory response to improve functionality of canines diagnosed with osteoarthritis. 96% of the treatment group showed either increased passive range of motion, improved behavioral changes, or both compared to 4% for the placebo group. A randomized, blinded, placebo-controlled 14-day study of 60 dogs having prior veterinary-diagnosis OA in at least one limb joint. Two outcomes measuring the dog's quality of life were assessed: subjectively determined changes in eight behaviors associated with discomfort, and objectively determined changes in passive range of motion. BioElectronics' Model 088 device was secured near the cervical region of the dog's spine. PROM measures were taken at baseline and day 14. Behavioral measures were taken daily. Forty-nine animals completed the study. No negative side effects were reported. Average subjective discomfort scores for the treatment group were reduced from 4.26 to 2.31 compared to no improvement in the placebo group over the study period. Average PROM scores increased by 5.51 degrees relative to the placebo group. Ninety-six percent of the treatment group showed either increased PROM or improved behavioral changes or both compared to 4% for the placebo group. Most changes occurred within the first 8 days of treatment. Osteoarthritis is the most common type of arthritis in dogs and is the most common source of chronic pain in older dogs. This is due to the constant wearing away of the cartilage from dogs running, jumping, and other strenuous exercise. The prevalence of osteoarthritis can be as high as 20% in dogs more than a year old, with middle-aged and older dogs being at higher risk. Dogs that are diagnosed with arthritis tend to be lethargic, have difficulty moving from a sitting or lying position, cracking joints, stiffness, muscle wastage, and visible pain. Current treatment options for arthritis are typically NSAIDs given alone or in combination with other disease-modifying agents. In recent years, chronic use of NSAIDs has been linked to numerous side effects, including gastrointestinal bleeding, and renal and hepatic dysfunction. Anti-inflammatory drugs such as aspirin and ibuprofen may also result in side effects, such as GI bleeding. BioElectronics Model 088 applied at the cervical spine level, may have the potential to significantly improve the quality of life for dogs and other small domestic animals with OA. Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device into the veterinary medicine market.

08:59 EDT Omniq enters partnership with SPAR International - OMNIQ announced a strategic partnership with SPAR international. This collaboration will see the deployment of OMNIQ's cutting-edge self-checkout and ESL systems. The Netherlands-based retailer operates in 49 countries and has recently expanded to the Israeli market. OMNIQ deployed self-checkout systems designed for this project. This initiative underscores SPAR's commitment to enhancing customer convenience, streamlining shopping experiences, and offering competitive prices. By integrating OMNIQ's solutions, SPAR aims to significantly reduce wait times, improve operational efficiency, and foster a more sustainable shopping environment. This collaboration not only reflects SPAR's dedication to innovation but also solidifies its position as a leader in the retail sector, keen on adopting solutions that benefit consumers and communities alike.

08:57 EDT Blue Star Foods starts soft-shell crab season - Blue Star Foods announced that its soft-shell operations in South Carolina have started production for the 2024 season under its existing license from the South Carolina Department of Natural Resources.

08:56 EDT Open Lending CEO Keith Jezek steps down, Chuck Jehl named COO, interim CEO - Open Lending announced that Keith Jezek is stepping down as Open Lending's CEO and as a member of its Board of Directors. Effective immediately, the Board has appointed Chuck Jehl, CFO, as COO and Interim CEO in an expanded role. Mr. Jezek will remain available to the Company to advise in leadership transition matters, and the Board has initiated a comprehensive process to identify a permanent CEO. In addition to serving as Interim CEO and COO, Mr. Jehl will remain the Company's CFO during this process.

08:54 EDT Global Mofy Metaverse explores partnership on metaverse, AI technology - Global Mofy Metaverse revealed that three-way strategic cooperation discussions were initiated with a senior professor from a renowned medical university in Beijing and his director team of its affiliated hospital, as well as the Metaverse Committee of the Beijing Big Data Association. The goal is to combine Metaverse and AI technologies with traditional Chinese and Western healing methods. This partnership aims to explore the vast potential for researchers, healthcare practitioners, and patients to harness the benefits of integrating these technologies into preventive healthcare and various treatments. During the initial meeting, the team outlined a strategic approach focused on developing a system for training and education using virtual reality. This includes creating virtual interactive platforms for hands-on training, leveraging data analytics for enhanced learning experiences, and conceptualizing a virtual professor role to facilitate online training. These initiatives are aimed at transforming educational methodologies in healthcare, aligning with the futuristic vision of the partnership.

08:53 EDT Oatly Group enters distribution agreement with Virgin Voyages - Oatly Group announced a new distribution arrangement with Virgin Voyages. Now available within all cafes across the Virgin Voyages fleet, Oatly Barista Edition serves as the travel brand's official oatmilk of choice for all guests aboard, also referred to as Sailors.

08:51 EDT DiamondRock announces retirement of General Counsel Bill Tennis - DiamondRock Hospitality announced that Bill Tennis, its long-time Executive Vice President and General Counsel, will retire effective June 30, 2024. Tennis, who joined the Company in 2010, has played a leading role in representing the Company in many of its strategic decisions and has been a trusted advisor to the Chief Executive Officer and other Company executives. Tennis received his undergraduate degree from Harvard University and his juris doctor from The New York University School of Law.

08:50 EDT Montage Gold appoints Tia as Chief Financial Officer - Montage Gold Corp. announcse the strengthening of its leadership team with the appointment of Constant Tia to the position of Chief Financial Officer, effective July 1, 2024. Constant will succeed Glenn Kondo, current CFO of Montage, who as announced on November 28, 2023, accepted the role of CFO of Lucara Diamond Corp., also within the Lundin Group of Companies. In order to ensure a smooth transition, Glenn has agreed to support Constant over the next few months.

08:50 EDT Lilium appoints Johan Malmqvist as CFO - Lilium appointed Johan Malmqvist as CFO effective April 1, 2024. Most recently, Johan served as CFO at a premium electric vehicle manufacturer, Polestar Automotive Holding. Johan succeeds Oliver Vogelgesang, who has been with Lilium since 2021 when he joined as SVP Finance & Controlling.

08:49 EDT Blink Charging appoints Jenifer Yokley as CMO - Blink Charging has promoted Jenifer Yokley to the position of Chief Marketing Officer. Having previously served as Blink's Sr. Vice President of Marketing and Head of Governmental Affairs, Yokley's elevation to CMO comes on the heels of the Company's recent record fourth-quarter earnings announcement and the opening of its new global headquarters.

08:47 EDT Marathon Digital launches MARAFW, MARA UCB 2100 control board - Marathon Digital Holdings launched MARAFW and MARA UCB 2100, industry leading firmware and a control board designed to improve the performance, efficiency, and versatility of various Bitcoin mining rigs. For the past year, Marathon has been developing and testing MARAFW and MARA UCB 2100 control board as part of its vertical tech stack to optimize performance. The Company is currently rolling out MARAFW across its fleet of more than 200,000 Bitcoin mining rigs. Given the positive results of these initial rollouts, Marathon is now offering both MARAFW and MARA UCB 2100 to the broader Bitcoin mining community. Marathon has already successfully sold MARAFW and MARA UCB2100 to multiple enterprise clients. The Company is now providing all interested miners with the opportunity to experience some of the unique technology that sets Marathon apart.

08:46 EDT Locafy launches Hotfrog Proximity Page in collaboration with Yext - Locafy (LCFY) announced the launch of Hotfrog Proximity Page, an application built in partnership with Yext (YEXT). Hotfrog Proximity Page is a proprietary application that allows users to enhance their online presences and drive traffic to their main websites. Locafy's technology already uses the information included on Hotfrog.com, a top-20 free online directory which Locafy acquired in 2016, to create new landing pages.. This solution combines data from Yext's headless CMS, Yext Content, with Locafy's specialized SEO technology to empower local businesses to effortlessly create for themselves one or more dynamic landing pages that are optimized for SEO performance.

08:45 EDT ZyVersa Therapeutics expects cas to fund requirements on month-to-month basis - Based on its current operating plan, ZyVersa expects its cash of $3.1 million as of December 31, 2023 will be sufficient to fund its operating expenses and capital expenditure requirements on a month-to-month basis. ZyVersa will need additional financing to support its continuing operations. ZyVersa will seek to fund its operations through public or private equity or debt financings or other sources, which may include government grants and collaborations with third parties.

08:41 EDT Aveo Oncology appoints Edgar Braendle as CMO - AVEO Oncology announced the appointment of Edgar Braendle, MD, PhD as AVEO Oncology's new Chief Medical Officer. Dr. Braendle is a life sciences executive with experience spanning from early drug discovery to the launch of small molecules, biologics, radiopharmaceuticals, gene and cell therapies, and medical device development. Braendle brings more than twenty years of clinical research experience to AVEO Oncology, most recently serving as Chief Development Officer of Autolus Therapeutics. AVEO Oncology, an LG Chem company, and LG Chem Life Sciences also announced the formation of its Scientific Advisory Committee. This esteemed group of experts in oncology research and clinical development were selected to advise and bring unique perspectives to AVEO and LG Chem's clinical strategy and business development initiatives.

08:38 EDT Emergent BioSolutions receives NAI status for Baltimore Bayview facility - Emergent BioSolutions announced that the U.S. Food and Drug Administration has listed "No Action Indicated" or NAI status classification for the company's Baltimore Bayview manufacturing facility. Based on this outcome, the Baltimore Bayview facility is considered to be in an acceptable state of compliance with regard to current good manufacturing practices.

08:37 EDT ContextLogic urges stockholders to vote for Qoo10 transaction - ContextLogic reminded stockholders to vote "FOR" the proposed Asset Sale transaction with Qoo10 in advance of the special meeting of its stockholders scheduled for April 12, 2024. ContextLogic stockholders of record at the close of business on March 7, 2024, are entitled to vote at or in advance of the Special Meeting. The Company currently estimates that its post-closing cash would range between $150-157 million, assuming an April 16th closing. The transaction preserves $2.7 billion of net operating losses, which the Company plans to work expeditiously to utilize. After reducing substantially all of the Company's cash burn, the post-closing Board will conduct a careful and extensive review of available opportunities for the Company's NOLs. A potential dissolution or premium cash takeout would net less for stockholders than the current transaction price and destroy the value of the NOLs. The Company expects to complete the transaction in the second quarter of 2024, subject to the approval of ContextLogic's stockholders and other customary closing conditions.

08:35 EDT Greenwave Technology's second shredder being connected to power grid - Greenwave Technology Solutions (GWAV) announced that Dominion Energy (D) is currently in the process of connecting its second automotive shredder to the power grid which is expected to be completed by March 29, 2024. The Company's second automotive shredder is expected to commence operations shortly thereafter and double Greenwave's annual shredded ferrous output. "Greenwave's second shredder provides the infrastructure for us to expand our footprint of metal recycling facilities up from 13 currently - significantly growing Greenwave's revenues, margins, and free cashflow," stated Greenwave CEO Danny Meeks. "We believe the market is significantly undervaluing Greenwave and firmly believe that by continuing our hub-and-spoke strategy of shredder hubs with feeder yards, we will become an increasingly attractive acquisition target of the major scrap metal conglomerates."

08:35 EDT Boeing gains 3% to $194.55 following announcement of CEO stepping down

08:34 EDT AbbVie to acquire Landos Biopharma got $20.42 per share in cash - AbbVie (ABBV) and Landos Biopharma (LABP) announced a definitive agreement under which AbbVie will acquire Landos. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist with a bimodal mechanism of action, which is anti-inflammatory and facilitates epithelial repair. "With this acquisition, we aim to advance the clinical development of NX-13, a differentiated, first-in-class, oral asset with the potential to make a difference in the lives of people living with ulcerative colitis and Crohn's disease," said Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, AbbVie. Under the terms of the agreement, AbbVie will acquire Landos at a price of $20.42 per share in cash upon closing, or approximately $137.5 million in the aggregate, plus one non-tradable contingent value right per share with a value of up to $11.14 per share, or approximately an additional $75 million in the aggregate, subject to the achievement of a clinical development milestone. The proposed transaction is expected to close in the second calendar quarter of 2024, subject to customary closing conditions, including approval by Landos' stockholders.

08:33 EDT DZS working with Connect2First, City of Cabot to bridge digital divide - DZS and its strategic partner Irby Utilities announced that they are working with Connect2First, a subsidiary of First Electric Cooperative, and the City of Cabot, Arkansas to build the first city-owned high speed fiber internet and telephony network in Arkansas. The City of Cabot and Connect2First are leveraging Irby's broadband network planning and deployment expertise along with cutting-edge DZS Access and Subscriber Edge fiber access solutions to bring 10 gigabit per second symmetrical passive optical networking driven next-generation digital communications services to the over 26,000 residents and businesses of Cabot.

08:32 EDT B. Riley Financial appoints Schnippel as Managing Director - B. Riley Financial announced the addition of Virginia Schnippel as a Managing Director within the Corporate Advisory & Valuation Services practice at B. Riley Advisory Services.

08:29 EDT Algoma Steel announces proposed offering of senior secured second lien notes - Algoma Steel Group announced that its indirect wholly-owned subsidiary, Algoma Steel, intends to offer for sale US$350 million aggregate principal amount of Senior Secured Second Lien Notes due 2029. The Notes will be guaranteed on a senior secured basis by ASI's immediate parent company and all of ASI's subsidiaries. Pricing and consummation of the offering of the Notes are subject to market and other conditions. ASI intends to use the net proceeds from the offering of the Notes for general corporate purposes, adding strength and flexibility to its balance sheet.

08:27 EDT Par Pacific announces amendment to ABL credit facility - Par Pacific Holdings announced that, on March 22, 2024, it entered into the previously announced amendment to its asset-based revolving credit facility. The ABL amendment will increase the size of the Company's ABL from $900 million to $1.4 billion and is conditioned upon the termination of the Company's existing intermediation agreement, which is expected to occur on or about May 31, 2024. The increase is based, in part, on the addition of certain collateral assets in Hawaii, including refined product inventory and accounts receivable. In addition, the Company announced that Moody's Investors Service has upgraded its corporate family rating to Ba3 from B1.

08:26 EDT Dirtt Environmental announces results of substantial issuer bid, tender offer - DIRTT Environmental Solutions announced the results of its substantial issuer bid and tender offer commenced on February 15, 2024, as varied on March 5, 2024 to repurchase for cancellation: up to C$6,000,000 principal amount of its issued and outstanding 6.00% convertible unsecured subordinated debentures due January 31, 2026 at a purchase price of C$720 per C$1,000 principal amount of January Debentures; and up to C$9,000,000 principal amount of its issued and outstanding 6.25% convertible unsecured subordinated debentures due December 31, 2026 at a purchase price of C$600 per C$1,000 principal amount of December Debentures. The Offer expired on March 22, 2024 at 5:00 p.m. Based on the final report provided by the depositary for the Offer, C$4,693,000 aggregate principal amount of January Debentures and C$5,775,000 aggregate principal amount of December Debentures were validly deposited and not withdrawn at the expiration of the Offer, representing approximately 11.66% of the January Debentures and 16.50% of the December Debentures issued and outstanding. The Company will take up all of the Debentures tendered pursuant to the Offer for aggregate consideration of approximately C$6,843,960. The aggregate purchase price for the January Debentures validly deposited under the Offer will be approximately C$3,418,304.05 and the aggregate purchase price for the December Debentures validly deposited under the Offer will be approximately C$3,546,087.33. Such aggregate purchase prices include all accrued and unpaid interest on such Debentures up to, but excluding, March 22, 2024, the date the Debentures were taken up by the Company pursuant to the Offer. Payment of the purchase price for the Debentures validly deposited and accepted for purchase will be made to the Depositary in accordance with the terms of the Offer and applicable law on or around March 25, 2024. Following the purchase and cancellation of the Debentures validly deposited and taken-up under the Offer, the Company will have C$35,557,000 principal amount of January Debentures and C$29,225,000 principal amount of December Debentures issued and outstanding.

08:25 EDT Tonix Pharmaceuticals receives Rare Pediatric Disease designation for TNX-2900 - Tonix Pharmaceuticals announced the U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation to TNX-2900, a proprietary magnesium potentiated formulation of intranasal oxytocin, to treat Prader-Willi syndrome in children and adolescents. TNX-2900 was previously granted Orphan Drug designation by the FDA in 2022 for the treatment of PWS and the investigational new drug application was cleared by the FDA in 2023. The Company may be eligible to receive a transferable Priority Review Voucher if TNX-2900 for PWS is approved for marketing. Recently, vouchers have sold for approximately $100 million.

08:24 EDT Ree Automotive P7-C receives CARB certifications - REE Automotive has received two certifications from California Air Resources Board on the Class 4 P7-C chassis cab. The two certifications include Phase 2 Greenhouse Gas covering the complete vehicle and the new Zero Emission Powertrain certification. In addition to California, several other states are expected to adopt the Phase 2 GHG and ZEP requirements in the coming years. CARB certification is a requirement for eligibility for several state incentives, which combined with federal can total over $100,000 per vehicle depending on customer location. California and several other states have indicated plans to adopt the Advanced Clean Truck Regulation, a manufacturers sales requirement to sell growing percentages of electric trucks, and requires ZEP certification.

08:22 EDT Disney reaffirms call for change in composition of Disney board - The Trian Group, which beneficially owns over $3.5B of common stock in The Walt Disney Company, reaffirmed its call for change in the composition of the Board of Directors of Disney and the commitment of its nominees, Nelson Peltz and Jay Rasulo, to work constructively with the Company's Board and leadership team to drive long-term, sustainable value creation. The investment firm has issued a letter stating: "Trian believes that Disney is the most advantaged consumer entertainment company in the world. Over the last one, three, five and ten years, however, Disney has woefully underperformed its potential and its peers, costing shareholders more than $200 billion in value. Accordingly, Trian believes that change is needed. Ahead of the Disney annual meeting of shareholders on April 3, 2024, Trian encourages all shareholders to vote FOR its two candidates, Mr. Peltz and Mr. Rasulo, and to withhold support from two incumbent directors, Maria Elena Lagomasino and Michael B.G. Froman. Trian believes Disney's problems lay at the feet of the Board, which lacks focus, alignment and accountability. Although the Board members are accomplished professionals, they are extraordinarily busy, have invested almost none of their own money in Disney stock and have failed to heed investor input. The result has been questionable strategic and capital allocation decisions, including the investment of $200 billion of capital without any discernible return, the demonstrable lack of alignment between executive compensation and shareholder value creation and financial results in the most recent year that pale in comparison to the results five years ago. Most recently, the Board botched its most important job - CEO succession - by installing Bob Chapek in that role seemingly without appropriate vetting or oversight. The Board then renewed Mr. Chapek's contract just months before firing him for poor performance. Ultimately, the Board had to call Bob Iger out of retirement to fill the void. In this election contest, Disney has emphasized that Mr. Iger is admired and respected (including, for example, by service providers and advisors), which we do not doubt. Trian supports Mr. Iger as a candidate for the Board and as CEO. That Disney spends so much time and ink defending Mr. Iger - while saying almost nothing about the two director candidates whose reelection Trian is challenging - is both troubling and telling. This campaign is not about Mr. Iger, nor is it a referendum on his leadership. And in all events, Disney is, and must be, more than just one person, especially one whose contract expires in less than two short years. This election is a board election and the question before shareholders is: who should serve on the Board, helping the company on behalf of shareholders? We have nominated two candidates, Mr. Peltz and Mr. Rasulo, who have a shareholder mindset, extensive, relevant experience and a willingness to ask tough questions and set demanding goals. Mr. Peltz has served on eleven public company boards, including at some of the most respected companies in the world. Mr. Rasulo is the former Chief Financial Officer of Disney and knows the business well. Disney's board seemingly does not want their help - claiming they will be "disruptive" - and prefers instead its hand-selected incumbents, an expert in foreign affairs and an advisor to wealthy families. Choosing between these slates, and voting for change versus more of the same, is really what this election is about. Our nominees' goal is to delight Disney's customers and to enhance value for all shareholders. To that end, Mr. Peltz and Mr. Rasulo look forward to working collaboratively with the executive team and Board - as they have done many times before at other companies - when they are elected. Mr. Rasulo worked in that manner at Disney previously. Mr. Rasulo and Mr. Iger worked side-by-side every day for more than five years as CFO and CEO, collaborating for the good of Disney shareholders. If elected, Mr. Rasulo would bring his extensive knowledge of Disney and its culture, people, operations and customers to the boardroom, and be an independent source of knowledge about the industry and the company. In 2019, Mr. Peltz was asked by Mr. Iger to address the Disney Board about shareholder sentiment in the media industry. Mr. Peltz was happy to do so, and the discussion was seemingly productive and interactive. More generally, Mr. Peltz has a reputation as a productive and insightful corporate director. His colleagues on corporate boards, across industries, have regularly renominated him as a director, and he has been elected by shareholders more than 50 times to serve as their representative - almost always garnering more than 90% of the vote. He did not amass that record by being disruptive or unproductive. Disney knows from its own experience that Mr. Peltz is a willing and helpful collaborator. But if there were any doubt, last week, thirteen of Mr. Peltz's current and former colleagues wrote an open letter to Disney's Board in which they said of Mr. Peltz that he: "entered the boardroom every meeting with an open mind, a focus on growth for the benefit of stakeholders and a commitment to working constructively towards our common goal of creating long-term shareholder value." We believe that reelecting the existing Board will have the predictable effect of leading to more of the same: questionable strategic and capital allocation decisions, poor executive compensation alignment and suboptimal succession planning. Trian is convinced that Mr. Peltz and Mr. Rasulo can assist Disney with its challenges and help ensure a brighter future."

08:21 EDT Verizon Business unveils 'Experiences Room' at Enterprise Connect - Verizon Business has unveiled a 5G and AI-powered Experiences Room as well as a host of mobile workplace collaboration tools and cloud-connected calling solutions at this year's Enterprise Connect. "Businesses have access to more communications, collaboration and cloud tools and solutions than ever before, but putting it all together can be daunting," said Alex Doyle, VP of Product, Verizon Business. "The goal of our Experiences Room and the demonstrations at our booth is to illustrate how Verizon Business' forward-looking solutions can be applied in real-world scenarios today, whether you're a small business, a global enterprise, or a government agency."

08:19 EDT Smith & Nephew partners with UFC as sports medicine technology provider - Smith+Nephew has been named the Preferred Sports Medicine Technology Partner of UFC - the world's premier mixed martial arts organization and one of the foremost global brands in all of sports. Under the terms of the multi-year partnership, Smith+Nephew will activate its brand through UFC's immense global presence to promote the repair, regeneration and recovery of Sports Medicine injuries through advanced technologies

08:18 EDT Camtek receives an order for approximately $25M from tier-1 manufacturer - Camtek announced that it has received a new order for approximately $25 million from a tier-1 HBM manufacturer, for the inspection and metrology of High Bandwidth Memory. Most of the systems are expected to be delivered in the second half of 2024. Rafi Amit, CEO of Camtek commented, "I am pleased with this order that continues the momentum of orders for HBM from the second half of 2023. Camtek systems continue to be the tool of choice by major manufacturers supporting the increased demand of HBM. This order improves our visibility for the second half of 2024. We anticipate more orders for HBM later this year, which is expected to be a record year for Camtek."

08:17 EDT Daxor acquires Volumex, Megatope for Iso-Tex Diagnostics - Daxor entered into a definitive agreement to acquire exclusive and worldwide rights and intellectual property to manufacture from its existing supplier for Volumex and Megatope from privately-held Iso-Tex Diagnostics, Inc. Daxor has also acquired the exclusive rights to Glofil, a drug that measures glomerular filtration rate, which Iso-Tex has been selling directly to its customer base. Daxor projects the acquisitions to be cash flow positive and accretive to earnings immediately upon transfer of the manufacturing. This is due to the embedded revenue streams of the drugs and significantly higher margins that will be achieved with internalized production. The deals have been structured with seller-provided financing on favorable terms. No payments will come due until manufacturing is fully transitioned to Daxor over the next 6-9 months. The total transaction value will then be paid in monthly installments over two years from that point, with payments anticipated to be supported by the revenue from Glofil and cost-savings from in-house manufacture of BVA test kits. The transaction is subject to customary conditions, including receipt of applicable regulatory approvals.

08:15 EDT Rhythm announces first patient dosed in Phase 1 trial of RM-718 - Rhythm Pharmaceuticals announced that the first patients have been dosed in the Company's Phase 1 clinical trial of RM-718, an investigational, weekly melanocortin-4 receptor- specific agonist designed to be MC1R-sparing and to potentially avoid hyperpigmentation. This Phase 1 trial is a three-part study to evaluate safety, tolerability and pharmacokinetics. The study consists of Part A: single ascending doses of RM-718 in healthy participants 18 to 55 years old with obesity; Part B: multiple ascending doses of RM-718 in healthy participants 18 to 55 years old with obesity; and Part C: MAD of RM-718 in patients 12 to 65 years old with hypothalamic obesity. Cohorts in Parts A and B are double-blind, placebo-controlled, and randomized 2:1. Study participants will receive one weekly dose of either RM-718 or placebo in Part A, four weekly doses of either RM-718 or placebo in Part B, and four weekly doses of open-label RM-718 in Part C. RM-718 or placebo doses are administered weekly via subcutaneous injection. The anticipated enrollment for this study is 96 participants.

08:14 EDT Taseko Mines enters agreement to acquire 100% of Gibraltar Mine - Taseko Mines announces that it has entered into a definitive agreement to acquire the remaining 12.5% interest in the Gibraltar Mine from Dowa Metals & Mining Co and Furukawa Co. Under the terms of the Agreement, Taseko will acquire Dowa and Furukawa's shares in Cariboo Copper Corp and will then own 100% of Cariboo shares and have an effective 100% interest in the Gibraltar Mine. An initial $5 million payment will be made to Dowa and Furukawa shortly following closing. The remaining cash consideration will be repayable in annual payments commencing in March 2026. The annual payments will be based on the average LME copper price of the previous calendar year, subject to an annual cap based on a percentage of cashflow from the Gibraltar Mine. The annual payments also can not exceed 6.25% of Gibraltar's annual cashflow for the 2025 to 2028 calendar years, and 10% of Gibraltar's cashflow for the 2029 to 2033 calendar years. Any outstanding balance on the minimum acquisition amount of $117 million will be repayable in a final balloon payment in March 2034. Total consideration is capped at $142 million, limiting the contingent consideration to a maximum of $25 million. In addition, Taseko has the option to settle the full acquisition price at any time prior to 2029 by making total payments of $117 million.

08:14 EDT Boeing CEO Dave Calhoun to continue to lead Boeing through year-end - Boeing President and CEO Dave Calhoun announced his decision to step down as CEO at the end of 2024, and he will continue to lead Boeing through the year to complete the critical work underway to stabilize and position the company for the future. In a letter to employees, Calhoun said: "As you all know, the Alaska Airlines Flight 1282 accident was a watershed moment for Boeing. We must continue to respond to this accident with humility and complete transparency. We also must inculcate a total commitment to safety and quality at every level of our company. The eyes of the world are on us, and I know we will come through this moment a better company, building on all the learnings we accumulated as we worked together to rebuild Boeing over the last number of years... I am confident that the way we have confronted these challenges, and how we are responding to this specific moment, is establishing standards for future generations of employees and will be woven into the fabric of how we operate for decades to come... I have been considering for some time, in discussion with our board of directors, the right time for a CEO transition at Boeing. I want to share with you that I have decided this will be my last year as CEO of our great company, and I have notified the board of that decision."

08:13 EDT Gildan Activewear shareholder Turtle Creek sees company value at over $60/shr - Turtle Creek Asset Management, a decade-long shareholder of Gildan Activewear issued an open letter to the board of directors of Gildan, stating: "Turtle Creek is a long-term and engaged owner of Gildan. We are deeply troubled with the Board's latest attempt to avoid the judgement of its shareholders through a purported process to sell the Company. This Board does not have a mandate, nor the confidence of Gildan shareholders, to run a process that could result in the sale of Gildan. The Board's outrageous and unprecedented actions to date, in the face of massive shareholder opposition are wholly-disqualifying. In fact, we strongly believe that the Board has initiated a sale process in a desperate attempt to avoid the profound professional embarrassment that will befall the directors once they are voted off the board by Gildan's shareholders. If a meeting of Gildan shareholders were held today, we have a high level of confidence that the shareholders would vote overwhelmingly in favor of the individuals nominated by Browning West LP. Even the release of the news of the sale process was characteristic of the Board's slapdash approach to governance. The material disclosure that the Board was attempting to sell the Company was reported on by the news media, during regular market hours, citing an emailed statement from a Gildan spokesperson. Unsurprisingly, this prompted regulators to halt trading in Gildan shares approximately 20 minutes later for the duration of the trading day. In the ensuing hours, detailed information about the names of third parties who had indicated interest in purchasing Gildan, along with indicative pricing levels, began appearing in the news media, demonstrating a lack of integrity in the purported process. These leaks ran counter to the interests of potential buyers, which led us to speculate that they originated from Gildan or its advisors. To even a casual market observer, it is so obviously a bad time to initiate a sale process that we have been left stunned in disbelief. Public companies frequently receive unsolicited purchase offers. Just because an offer has been received does not require the Board to seriously entertain it, especially when the Company is in the midst of a boardroom battle. Turtle Creek believes that the process led by the Special Committee is yet another attempt by the Board to evade accountability for its actions. We are concerned that the "sale process" is, at best, a hasty attempt to sell the Company at a price that does not reflect Gildan's long term potential, or, at worst, a cynical and irresponsible tactic intended to provide a pretext to further delay or influence the annual meeting of Gildan shareholders. For over 25 years, Turtle Creek has done the hard work of analyzing and valuing the companies in which we invest. We think about what the future holds for our companies and the future cash flows the companies could generate. When we do our analysis of Gildan, we arrive at a value of over US$60 per share. Clearly, Gildan is trading at a substantial discount to our view of its value. We and other shareholders do not trust the current Board to act as independent fiduciaries for us. We demand the Board hold the annual meeting of shareholders on an urgent basis and allow shareholders to elect a new Board before further, permanent harm is caused to the Company. We remain steadfast in our resolve to see substantial Board change. The Board still has an opportunity to do the right thing and put an end to an unfortunate chapter in the Company's history."

08:13 EDT Sun Life Financial appoints Deacon as Chief Financial Officer - Sun Life Financial announces the appointment of Timothy Deacon as Executive Vice-President and Chief Financial Officer, reporting to Kevin Strain, President and CEO, Sun Life, effective April 8, 2024. Mr. Deacon will become a member of Sun Life's global Executive Team. He succeeds Manjit Singh, who is now President of Sun Life Asia. Singh will continue in his role as President of Sun Life Asia and as CFO until Deacon assumes his new role.

08:12 EDT Boeing independent board chair Larry Kellner won't stand for reelection - Boeing said Board Chair Larry Kellner has informed the board that he does not intend to stand for re-election at the upcoming Annual Shareholder meeting. The board has elected Steve Mollenkopf to succeed Kellner as independent board chair. In this role, Mollenkopf will lead the board's process of selecting Boeing's next CEO.

08:09 EDT Kidpik regains compliance with Nasdaq - Kidpik announced that the company received written notification from the Listing Qualification Department of Nasdaq notifying the company that is has regained full compliance with the minimum bid price requirement. Effective March 7, the company affected a 1-for-5 reverse stock split of our outstanding stock in an effort to satisfy the minimum bid price requirement; as a result Nasdaq has determined that for 10 consecutive days the closing bid price of the company's common stock was at or above $1.00 per share, and that the matter is now closed.

08:08 EDT Manulife reinsure $5.8B of reserves of low ROE Canadian Universal Life block - Manulife Financial Corporation announced it has agreed to reinsure $5.8B of reserves of low ROE Canadian Universal Life block to RGA Life Reinsurance Company of Canada. Roy Gori, Manulife President & Chief Executive Officer said, "This transaction is the largest Universal Life reinsurance transaction in the Canadian insurance industry and represents another milestone in our journey to transform our portfolio to higher ROE and lower risk businesses. This deal, valued at 16.2 times earnings and priced at book value further demonstrates our focus and ability to execute on attractive terms and our commitment to unlocking shareholder value. With this transaction, we will have released $11 billion of capital since 20185 and improved Core ROE by ~5% since 2017. We remain highly focused on exploring additional organic and inorganic actions to deliver value to shareholders."

08:07 EDT YASSI named to Guidewire's Insurtech Vanguards program - Yotta Automated Software Solutions, YASSI, announced that the company has joined Guidewire's Insurtech Vanguards program, a new initiative led by property and casualty cloud platform provider, Guidewire, to help insurers learn about the newest insurtechs and how to best leverage them. "We are excited to welcome YASSI to the Insurtech Vanguards program," said Laura Drabik, Chief Evangelist at Guidewire. "YASSI's innovative approach to providing real-time vehicle data aligns with our mission to empower insurers with cutting-edge technology. Their solutions not only streamline operations but also enhance the overall experience for policyholders, making a significant impact on the industry. We look forward to supporting YASSI in their journey and exploring the value they bring to our customers and the insurance ecosystem at large."

08:06 EDT Arrowhead begins EAP to avail plozasiran outside of trials for patients with FCS - Arrowhead Pharmaceuticals announced that it has initiated an Expanded Access Program EAP to make investigational plozasiran available outside of a clinical trial for patients with familial chylomicronemia syndrome FCS who meet certain program eligibility criteria. Arrowhead will also present new final Phase 2 clinical data from the double-blind portion of the SHASTA-2 study of plozasiran in a late-breaking oral presentation at the upcoming American College of Cardiology 73rd Annual Scientific Session & Expo ACC.24 , being held in Atlanta on April 6-8, 2024. "Arrowhead is committed to supporting patients living with various lipid disorders and the physicians who treat them. To that end, we are pleased that Dr. Daniel Gaudet, Professor of Medicine at Universite de Montreal and President and Scientific Director of ECOGENE-21, will present final data in a late-breaking oral presentation at ACC.24 from the SHASTA-2 study of plozasiran in patients with severe hypertriglyceridemia," said Bruce Given, M.D., interim chief medical scientist at Arrowhead. "Our Phase 3 PALISADE study of plozasiran in patients with FCS is nearing completion and we are further supporting the patient community by initiating an expanded access program for patients and physicians interested in receiving treatment with plozasiran outside of a clinical trial. In addition, Arrowhead medical affairs representatives will be hosting a company booth at ACC.24 with resources for physicians to learn more about the mechanism of cardiometabolic diseases we are studying and our pipeline of RNAi therapeutics that leverage Arrowhead's proprietary TRiM platform."

08:03 EDT GrowGeneration announces $6M share repurchase program - GrowGeneration announced that its board of directors has authorized the company's first share repurchase program to repurchase up to $6M of the company's outstanding common stock.

08:02 EDT Frontier Communications receives $24.7M in grant funding by Connect Illinois - Frontier received $24.7M in grant funding to expand high-speed fiber broadband service to homes and businesses in rural Illinois. The grant was awarded by Connect Illinois with the assistance of Greene County Economic Development Group.

07:59 EDT Ivanhoe completes earn-in to acquire 60% interest in Samapleu-Grata project - Ivanhoe Electric announced that Ivanhoe Electric has completed its earn-in to acquire a 60% interest in the Samapleu-Grata Nickel-Copper Project in the Ivory Coast. On March 21, 2024, Ivanhoe Electric's joint venture partner at the Project, Sama Resources, disclosed a new 2024 preliminary economic assessment for the Project in accordance with National Instrument 43-101. The Samapleu-Grata Nickel-Copper Project is now a 60/40 joint venture between Ivanhoe Electric and Sama. In addition to a 60% interest at the Project level, Ivanhoe Electric also owns 22.7% of the common shares of Sama. Taylor Melvin, President and CEO of Ivanhoe Electric commented: "We are pleased to have completed our earn-in to 60% of the Samapleu-Grata Nickel-Copper Project. We are particularly encouraged by the significant improvement in both the quality and quantity of potential future copper concentrate production at the Project compared to earlier studies. The results announced by our joint venture partner, Sama, are a product of the hard work by our dedicated joint team. We look forward to working together with Sama on the next steps for our high-quality nickel-copper Project." Ivanhoe Electric entered into a binding term sheet for an earn-in and joint venture agreement with Sama which was subsequently formalized in March 2021. Ivanhoe Electric satisfied the terms of its 60% earn-in by spending C$25 million by March 2024.

07:53 EDT AMC Networks announces proposed private offering of senior secured notes - AMC Networks intends to offer, subject to market conditions and other factors, $700 million aggregate principal amount of senior secured notes due 2029 in a private offering. The Notes will be unconditionally guaranteed, on a joint and several basis, by each of AMC Networks' existing and future domestic subsidiaries, subject to certain exceptions, on a senior secured basis. AMC Networks expects to use the net proceeds from the offering of the Notes, as well as cash on hand or other immediately available funds, to fund its tender offer to purchase for cash any and all of its outstanding approximately $775 million of 4.75% Senior Notes due 2025 and to redeem any 2025 Notes that remain outstanding after completion of the Tender Offer.

07:50 EDT Crown Castle urges shareholders to vote for director nominees - Crown Castle filed its preliminary proxy materials with the Securities and Exchange Commission in connection with its 2024 Annual Meeting of Stockholders to be held on May 22, 2024. In connection with the filing, the Company announced that the Board has nominated 12 directors to stand for election at the Company's Annual Meeting. Additionally, the Company issued the a letter to Crown Castle Shareholders, which lays out the steps that the Board is currently taking to create shareholder value and aims to set the record straight regarding certain statements made by Ted Miller and Boots Capital Management. The letter read in part, "The Crown Castle Board and management team believe that we have made significant strides over the last three months toward creating a stronger and more valuable company. We remain focused on the comprehensive strategic and operating review of the fiber and small cell business, in conjunction with Morgan Stanley, BofA Securities, Paul, Weiss and leading industry consultants. We also remain focused on the search for the Company's next CEO with the support of a leading executive search firm. We expect to share an update on the progress of these initiatives in the near future. The Board values feedback from all of its shareholders, and as we advance these initiatives, we are committed to acting in our shareholders' best interests by positioning Crown Castle for long-term success and value creation. Recently, Boots Capital and in particular one of its principals, Ted Miller, have publicly provided suggestions regarding our fiber and small cell business and the operations of our tower business. We believe a number of these statements are misleading to the market, and we want to ensure our shareholders have heard all of the facts...The Company is committed to correcting the record in the future as necessary. We remain confident that the actions we are already taking to orient the business for long-term success, which are in line with those suggested by Boots Capital, will enhance shareholder value and build on the Company's strong foundation."

07:47 EDT Dyne Therapeutics CEO Joshua Brumm to step down, John Cox to succeed - Dyne Therapeutics announced the appointment of John Cox as president, CEO and a member of the Board of Directors, effective immediately. He succeeds Joshua Brumm, who has chosen to step down from these roles to pursue a career in healthcare investing. Mr. Brumm will serve as an advisor to Dyne to help ensure a seamless transition. Most recently, Cox served as CEO of Repertoire Immune Medicines and its predecessor from 2019 until 2022.

07:44 EDT Blackwells says Nelson Peltz is not the change Disney's board needs - Blackwells Capital released a letter to fellow Disney shareholders in connection with the Company's Annual Meeting of Stockholders to be held on April 3, 2024, which read in part, " Blackwells Capital, a fellow shareholder of the Walt Disney Company, is soliciting your vote to elect Jessica Schell, Craig Hatkoff, and Leah Solivan to the board of directors of Disney at the Company's annual meeting of shareholders, which is scheduled to be held on April 3, 2024. The purpose of Blackwells' campaign is simple: to ensure that Disney has the right collection of minds around the boardroom table, working constructively together to make decisions that will benefit ALL shareholders for decades to come...The case for change is clear. Blackwells and its three nominees have identified certain governance failings at Disney that they believe can be corrected by adding to the Board the talents and capabilities that Blackwells' nominees offer. Most of the current Board has presided over substantial dollar market value declines.2 Certainly, extraneous events like the global pandemic had an impact, however, in our view, Disney's content and technology strategies are weak and its lack of transparency is stark-and the Board lacks real proficiency in these fields. Shareholders, particularly those who espouse the principals of good corporate governance and believe there is a need for change at Disney, do not have to accept the false dichotomy of Mr. Peltz or the status quo Board. The Board does not need nominees driven by personal grievances or animus towards management, as we believe Trian Partners' nominees Nelson Peltz and Jay Rasulo are. In our view, Mr. Peltz not only lacks critical expertise, but appears to boast about his shortcomings. Mr. Peltz may be one of America's most vocal investors, but he is also viewed as the "most overrated." Fifteen out of twenty-two companies where Trian has taken a board seat, have underperformed the S&P 500 during Trian's tenure on the board...In its recommendations, Institutional Shareholder Services, Inc. concluded that change is warranted at Disney, and we agree.10 Blackwells' nominees offer solutions drawn from real-life experiences to address Disney's issues and fill critical gaps on the Board. Blackwells' proposal-to add back any incumbent Disney director who loses the election to a non-Disney director-will also ensure that the necessary change is made in a collaborative and efficient manner."

07:39 EDT Venus Concept granted continued listing from Nasdaq hearings panel - Venus Concept received a decision from the Nasdaq Hearings Panel granting its request for continued listing on the Nasdaq Capital Market, subject to the Company demonstrating compliance with Nasdaq Listing Rule 5550(b)(1) or any of the alternative requirements under Nasdaq Listing Rule 5550(b) on or before May 28, 2024, and certain other conditions. On May 31, 2023, Nasdaq Listing Qualifications staff issued the Company a deficiency notice citing that the stockholders' equity as reported in the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2023, was below the minimum $2,500,000 required for continued listing under Nasdaq Listing Rule 5550(b)(1). On July 17, 2023, the Company submitted to the Nasdaq Staff a plan to regain compliance with the Minimum Equity Requirement. On July 28, 2023, the Nasdaq Staff granted an extension until November 27, 2023 to evidence compliance with the Minimum Equity Requirement, conditioned upon the Company's achievement of certain milestones as set forth in the Plan. On November 28, 2023, the Company received a written notice from the Nasdaq Staff which described its determination that the Company had not regained compliance with the Minimum Equity Requirement within the Plan period. On December 5, 2023, the Company requested a hearing, which was held on March 5, 2024, staying any delisting pending the issuance of the Panel's decision. At the Hearing, the Company presented a comprehensive compliance plan to regain compliance to the Nasdaq Panel and received the Panel Decision regarding the Nasdaq Listing Rules on March 20, 2024. Venus Concept continues to explore strategic alternatives to maximize shareholder value as part of the process announced on January 24, 2024. This includes engaging in dialogue with the Company's existing lenders and investors to find ways to best enable Venus Concept to achieve our operational and strategic objectives.

07:37 EDT Coherent announces optical circuit switch for data centers - Coherent Corp. announced the introduction of a new optical circuit switch based on the company's field-proven and ultrareliable Datacenter Lightwave Cross-Connect. Deploying an OCS-based architecture enables operators of artificial intelligence clusters to dramatically reduce the number of electrical switches required in data center networks, and, more importantly, reduces the costly optical-to-electrical-to-optical conversions that such electrical switches require. In an OCS, data signals remain in the optical domain as they transit the switch; eliminating OEO conversion can provide dramatic cost and power consumption savings. Furthermore, unlike traditional switches, the OCS does not need to be upgraded when the AI clusters are equipped with higher-speed connections in subsequent generations. For data centers, this significantly improves the return on capital expenditure.

07:36 EDT Luna Innovations CEO Scott Graeff retires - Luna Innovations announced that Scott Graeff has retired from his role as president and CEO of the company and has stepped down from the board of directors, leaving the company after 21 years, including the last seven as president and CEO. The board has initiated a search for a new president and CEO with the support of an international search firm. To oversee the company's operations while the search is ongoing, Richard Roedel, who has served as chairman of the board since 2010, has been appointed executive chairman and president on an interim basis. As interim executive chairman and interim president, Roedel will work closely with the company's leadership team.

07:35 EDT Theriva Biologics expects cash to provide runway into 1Q25 - Cash and cash equivalents totaled $23.2 million as of December 31, 2023, compared to $41.8 million as of December 31, 2022.

07:32 EDT Moleculin Biotech announces interim data on MB-106 - Moleculin Biotech provided a preliminary update on recent clinical activity and expected near term milestones for its lead program MB-106 for the treatment of Acute Myeloid Leukemia following its Fiscal Year 2023 filing with the Securities and Exchange Commission. The total CRs in both Phases to date in MB-106 represent a complete response composite rate of 39% in all currently evaluable, intent to treat subjects with two additional subjects recruited not yet evaluable. These subjects had 0-6 prior therapies. This is comprised of a CR rate of 33% and CRi of 6%. Durability data are developing with one CRc having relapsed to date. The first CR subject was treated in February 2023 and remains durable after over a year and continues in remission. Durability of CRs is confirmed by repeat bone marrow aspirates. The median age of all subjects recruited is 69, ranging from 19 to 78. Median durability will be established as the trial data mature. This trial may enroll up to 28 subjects, however, having already recruited the desired number of 2nd line subjects to support an EoP2 meeting with the FDA, the Company may elect to complete this trial with fewer than 28 subjects.

07:21 EDT Chemomab Therapeutics awarded European patent for CM-101 - Chemomab Therapeutics reported that the European Patent Office has granted a new patent for CM-101, Chemomab's first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that has been shown to play a critical role in the processes that drive fibrosis and inflammation. CM-101 is currently being assessed in the global Phase 2 SPRING trial for the treatment of primary sclerosing cholangitis. Patient enrollment in the trial has been completed, with a topline data readout expected midyear 2024. The new European patent covers the use of CM-101 and sequence-related anti-CCL24 antibodies for the treatment of hepatic diseases, including PSC. PSC is a potentially lethal condition that lacks any FDA-approved therapies and frequently requires liver transplantation. Unlike other drugs in development for PSC, CM-101 has a unique dual mechanism of action that simultaneously blocks fibrosis and inflammation. In clinical and preclinical studies, this distinctive approach has been shown to inhibit fibrogenesis and interfere with core PSC pathways. European Patent Application No. 18717135.0 "Anti CCL24 Antibodies for Use in the Treatment of Hepatic Diseases" has a grant date of March 20, 2024.

07:19 EDT Nuvation Bio to acquire AnHeart Therapeutics in all-stock transaction - Nuvation Bio and AnHeart Therapeutics announced that the companies have entered into a definitive agreement for Nuvation Bio to acquire AnHeart in an all-stock transaction. Immediately following the closing of the acquisition, the former shareholders of AnHeart will own approximately 33% and the current stockholders of Nuvation Bio will own approximately 67% of Nuvation Bio on a fully diluted basis. The acquisition, which has been approved by the board of directors of each company and is subject to approval by AnHeart's shareholders and other customary closing conditions, will position Nuvation Bio as a late-stage global oncology company with multiple programs in clinical development. The acquisition is expected to close in the second quarter of 2024. Nuvation Bio will continue to be led by its current management team, including David Hung, its founder, CEO, and president, and expects AnHeart's employees in China and the United States to join the Nuvation Bio team. Following the closing of the acquisition, Min Cui, founder and managing director of Decheng Capital, an investor in AnHeart, and Junyuan Jerry Wang, co-founder and CEO of AnHeart, will join the Nuvation Bio board of directors. At the closing of the acquisition, Nuvation Bio will issue to the AnHeart securityholders, in exchange for all outstanding AnHeart shares, options, and other securities, approximately 43,590,197 shares of Nuvation Bio's Class A common stock, 851,212 shares of Nuvation Bio's Series A Non-Voting Convertible Preferred Stock, and warrants collectively exercisable for 2,893,731 shares of Nuvation Bio's Class A common stock at an exercise price of $11.50 per share. Subject to approval by the Nuvation Bio stockholders, each share of Series A Non-Voting Convertible Preferred Stock issued by Nuvation Bio in the acquisition will initially be convertible into 100 shares of Class A common stock. Additionally, the warrants issued in the acquisition will be restricted until receipt of the Nuvation Bio stockholder approval. Any shareholders of AnHeart who are not accredited investors will receive cash for their AnHeart shares in lieu of receiving Nuvation Bio securities. The holders of approximately 90% of AnHeart's outstanding shares have entered into voting agreements, pursuant to which they have agreed to, among other matters, vote in favor of the acquisition. In connection with the execution of the definitive merger agreement, Hung entered into a voting agreement, pursuant to which he agreed to vote his shares of Nuvation Bio stock, representing approximately 27% of Nuvation Bio's outstanding shares, for the Nuvation Bio stockholder approval. The closing of the acquisition does not require the approval of the Nuvation Bio stockholders. Nuvation Bio and AnHeart intend that the acquisition will qualify as a tax-free reorganization. As AnHeart's parent company after the acquisition, Nuvation Bio will own all of AnHeart's assets, including AnHeart's intellectual property.

07:17 EDT Masimo shareholder Politan nominates two independent candidates to board - Politan Capital Management , Politan Capital Management an 8.9% shareholder of Masimo Corporation announced that it is nominating two candidates for election to the Masimo Board of Directors at the upcoming 2024 Annual Meeting of Stockholders . Quentin Koffey, Managing Partner and Chief Investment Officer of Politan, and a current director on the Masimo Board, stated: "When shareholders overwhelmingly elected Michelle Brennan and me to the Masimo Board last year, we were optimistic we could work productively with the rest of the Board to drive positive change. Unfortunately, our efforts were continually rebuffed, as Chairman & CEO Joe Kiani refused to give us basic information, denied us access to management, repeatedly held Board meetings excluding us, and refused to even consider allowing any review of capital allocation or strategy. Politan supports a strategic review to evaluate a separation of the Consumer Business as evidenced by our ongoing efforts over the last 18 months. However, at this stage the Board has been provided zero details, and Politan has serious concerns given the lack of basic governance and oversight we have observed since joining the Board. Information is controlled tightly by the Chairman & CEO and almost never shared.

07:15 EDT BeyondSpring reports first patient dosed with pembrolizumab, plinabulin plus EP - BeyondSpring announced that the first patient has been dosed in a Phase 2 investigator-initiated trial with Pembrolizumab, Plinabulin, BeyondSpring's lead asset, plus Etoposide/Platinum for first-line Extensive-Stage Small-Cell Lung Cancer. Current treatment for first-line ES-SCLC includes EP and EP plus PD-L1 antibodies. Although the objective response rate is high, median progression free survival remains low with median overall survival at 10-13 months. Therefore, 1L ES-SCLC remains a serious unmet medical need. Plinabulin, a potent dendritic cell maturation agent3, has been studied in a triple combination with various immuno-oncology agents and chemotherapy or radiation, with the potential to enhance the efficacy of PD-1/PD-L1 blockade and restore sensitivity in patients who become resistant. Preliminary re-sensitization data in PD-1/PD-L1 antibody failed patients in 8 cancer types corresponding response with Plinabulin DC maturation was presented at SITC conference in Nov 20234. This Phase 2 trial will evaluate the efficacy and safety of Pembrolizumab, Plinabulin plus EP in 1L ES-SCLC. The study5 is conducted in Wuhan Union Hospital in China, with Dr. Xiaorong Dong, Deputy Director of the Oncology Research Department and Director of the Thoracic Oncology Department, as the principal investigator. Patients enrolled are receiving the following interventional treatments. The primary endpoint is the 12-month PFS rate.

07:11 EDT Cellebrite appoints David Gee as CMO - Cellebrite DI (CLBT) announced the appointment of David Gee as Chief Marketing Officer. Mr. Gee brings more than 25 years of global sales and marketing expertise and will serve as a member of Cellebrite's executive leadership team, reporting directly to CEO Yossi Carmil. He will oversee Cellebrite's global marketing strategy and execution to help the Company capitalize on the major growth opportunities ahead in the digital investigations marketplace. Most recently, he served as CMO at Coherent (COHR).

07:10 EDT FDA approves AstraZeneca's Ultomiris for rare nerve disease NMOSD - ULTOMIRIS or ravulizumab-cwvz, has been approved in the United States as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 AQP4 antibody-positive Ab+ neuromyelitis optica spectrum disorder NMOSD . The approval by the US Food and Drug Administration FDA was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology. In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks and recurrent and may result in permanent disability.6-8 The diagnosed prevalence of adults with NMOSD in the US is estimated at approximately 6,000.9-11...Sean J. Pittock, MD, Director of Mayo Clinic's Center for Multiple Sclerosis and Autoimmune Neurology and of Mayo's Neuroimmunology Laboratory and lead primary investigator in the CHAMPION-NMOSD trial, said: "C5 inhibition has been proven to offer efficacy in reducing the risk of NMOSD relapses by blocking the complement system, a part of the immune system, from attacking healthy cells in the spinal cord, optic nerve and brain. With today's FDA approval, patients now have the option of a long-acting C5 inhibitor treatment that showed zero relapses in the pivotal CHAMPION-NMOSD trial, supporting the primary goal of relapse prevention in treating NMOSD."

07:08 EDT Cronos Group launches Lord Jones Chocolate Fusions - Cronos Group announced the launch of Lord Jones Chocolate Fusions, its first entry into the chocolate edibles category. Cronos' newest edible innovation was developed and designed by an expert team of culinary chefs, food scientists, and leaders in cannabis product development. The bite-sized Chocolate Fusions feature a dynamic, multi-texture experience, combining a soft and chewy center, crunch inclusions, and an outer layer of rich creamy chocolate that delivers a decadent sweet treat for adult cannabis consumers. Each package of Lord Jones Chocolate Fusions includes five pieces with 2mg of THC per piece. Lord Jones Chocolate Fusions launch in Ontario this month and will be available throughout Canada by mid-2024.

07:07 EDT Nurix Therapeutics part of team selected as Cancer Grand Challenges awardees - Nurix Therapeutics is part of a diverse research team of international experts selected as awardees in this year's Cancer Grand Challenges competition. The team includes scientists, physicians and patient advocacy groups from 10 institutions in the United States, the United Kingdom, France, Germany and Austria and will be led by Yael Mosse, M.D., Professor of Pediatrics and Patricia Brophy Endowed Chair in Neuroblastoma Research at the Children's Hospital of Philadelphia, and Martin Eilers, Ph.D., Professor of Biochemistry and Molecular Biology at the University of Wurzburg, Germany. The project entitled "Knocking Out Oncogenic Drivers and Curing Childhood Cancers" has the goal of developing orally bioavailable targeted protein degraders that have the potential to dramatically improve cure rates for children affected by solid tumors. In this first-of-its-kind industry/academic discovery partnership through Cancer Grand Challenges, Nurix will be making in-kind contributions to address each of the five onco-fusion targets, leveraging its DELigase technology to identify chemical starting points for drug design and providing key expertise in TPD optimization and development. Team KOODAC will focus on the development of TPDs and Molecular Glue Degraders to target five key and previously undruggable fusion proteins that have been shown to be drivers of high-risk solid tumors in pediatric patients, including, MYCN, EWSR1-FLI, DNAJB1-PRKACA, ALK, and PAX3/7-FOXO1, and conduct the preclinical studies needed for biomarker-driven clinical trials. The Cancer Grand Challenges is an initiative driven and funded by Cancer Research UK, whose goal is to facilitate identification of the greatest challenges in cancer today and to fund global teams to work in innovative ways to find solutions. This year, five teams were selected to receive funding of up to GBP 20 million over a period of five years. The funds, which will support only the academic groups involved in the project, will be managed by Team KOODAC.

07:05 EDT Well Health supports improvements in reimbursement policies - WELL Health Technologies announces its support of the recently announced reimbursement policies from a number of key Canadian provinces where WELL has significant clinical operations. In a significant move towards bolstering the healthcare system, the Provinces of Ontario, Alberta, and Manitoba have announced increases in reimbursement rates for primary care, specialized care, and diagnostic consultation codes. These new multi-pronged investments are designed to support a variety of care providers and promote a holistic approach to care, mirroring WELL's values in assisting the entire healthcare sector. This follows last year's innovative Longitudinal Family Practice reimbursement methodology implemented by British Columbia which was designed to boost funding for primary care physicians. All these adjustments are a response to the growing need for a robust support system for healthcare providers, aimed at addressing the challenges of inflation and the difficulties in attracting and retaining skilled physicians. WELL strongly supports these initiatives, recognizing them as crucial steps toward enhancing the healthcare landscape in Canada.

07:04 EDT Horizon Group expands portfolio with acquisition of Outlets at the Dells - Horizon Group Properties announces the acquisition of an interest in Outlets at the Dells. The center is situated in one of Wisconsin's leading tourist destinations. Outlets at the Dells is a favored shopping destination for tourists and residents alike. The center is now owned by three tenants in common, one of which is a subsidiary of Horizon Group Properties. Horizon has been hired by the owners to lease, manage, and market the property. Gary Skoien, CEO of Horizon Group Properties, conveyed his excitement about the acquisition, stating, "We are enthused by this opportunity and are dedicated to leveraging our extensive expertise in outlet and traditional retail operations, leasing, and marketing to further improve upon this outstanding shopping center. The addition of Outlets at the Dells to our portfolio furthers our objective of acquiring outlet centers in flourishing tourist regions."

07:02 EDT LTX by Broadridge integrates with TS Imagine - LTX, a subsidiary of global Fintech leader, Broadridge Financial Solutions, announced a successful integration with TS Imagine's Fixed Income Execution Management System, TradeSmart Fixed Income. The integration offers mutual buy-side clients improved pre-trade transparency, price discovery and better access to aggregated liquidity within their existing workflows. "Workflow integration has always been a key element to the LTX strategy as part of our mission to simplify and optimize, embedding new, innovative capabilities within the screens that our clients are familiar with," said AJ Cass, Head of Market Structure and Liquidity, LTX. "We're pleased to integrate with TS Imagine, bringing pre-trade transparency and trading efficiencies to our mutual clients' workflows."

07:01 EDT Ciena, DriveNets complete joint testing of ZR/ZR+ solution for cloud platform - DriveNets announced the completion of testing and certification of multiple Ciena 400G coherent pluggable transceivers integrated in the DriveNets Network Cloud platform. These successful tests demonstrate how the integrated DriveNets/Ciena solution can optimize service provider networks and build more efficient converged infrastructures. The solution also includes enhanced network configuration and management software capabilities and ensures the Ciena WaveLogic 5 Nano pluggables can be tuned, configured, and managed by DriveNets Network Cloud software.

06:51 EDT MAG Silver provides notice of updated Juanicipio technical report - MAG Silver will release results from its updated Juanicipio Technical Report on Wednesday, March 27, 2024. A conference call will be held to discuss the results of the Report on Wednesday, March 27, 2024 at 8:15 a.m. Eastern Time.

06:41 EDT eGain announces AssistGPT for CCaaS at Enterprise Connect - eGain announced the availability of its AssistGPT generative AI service for CCaaS at Enterprise Connect 2024, being held March 25-28 in Orlando, Florida. An integral part of the eGain Knowledge Hub and powered by Generative AI, AssistGPT is a comprehensive zero-code tool that helps automate the knowledge management lifecycle. An AI Console allows administrators to define controls and guard rails for the use of generative AI, manage prompts, and orchestrate Gen AI with other AI technologies in the enterprise.

06:39 EDT Hepsiburada to discontinue Hepsiburada Seyahat business - With effect from the close of business on March 31, 2024, Hepsiburada has made the commercial decision to discontinue its complementary business Hepsiburada Seyahat, which conducts airline and bus ticketing operations under a travel agency license granted in February 2021. The contribution of the Hepsiburada Seyahat business to the Company's GMV was not material for the year ended December 31, 2023. Any tickets sold prior to the discontinuance will remain valid and Hepsiburada will remain at the service of such ticketholders.

06:34 EDT Axsome Therapeutics says AXS-12 achieves primary endpoint in SYMPHONY trial - Axsome Therapeutics announced that AXS-12, a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, achieved the primary endpoint and significantly reduced the frequency of cataplexy attacks as compared to placebo in patients with narcolepsy in the SYMPHONY Phase 3 trial. AXS-12 also reduced excessive daytime sleepiness severity, improved cognitive function, and reduced overall narcolepsy severity as compared to placebo. SYMPHONY was a Phase 3 multicenter, randomized, double-blind, placebo-controlled trial in which 90 patients with a diagnosis of narcolepsy with cataplexy were randomized to treatment with AXS-12 or placebo for 5 weeks. AXS-12 met the primary endpoint by demonstrating a substantial and statistically significant reduction from baseline in weekly cataplexy attacks compared to placebo at Week 5, with reductions of 83% for AXS-12 and 66% for placebo. AXS-12 rapidly reduced weekly cataplexy attacks, demonstrating at Week 1 a reduction of 56% compared to a reduction of 31% for placebo. AXS-12 induced remission of cataplexy and increased cataplexy-free days compared to placebo. Remission of cataplexy, defined as a 100% reduction from baseline, was achieved at Week 5 by 33% of AXS-12 treated patients compared to 9.5% of placebo patients. Achievement of remission was rapid, being experienced at Week 2 by 24% of AXS-12 treated patients compared to 4.5% of placebo patients AXS-12 increased the percentage of cataplexy-free days per week, defined as days with zero cataplexy attacks, to 84.5% at Week 5 compared to 22.6% for placebo. AXS-12 significantly reduced excessive daytime sleepiness severity, assessed by the Clinician Global Impression of Severity scale for EDS, compared to placebo at Week 5 with mean reductions of 1.8 points for AXS-12 compared to 0.9 points for placebo. Rapid improvement on the CGI-S for EDS was seen as early as Week 1 compared to placebo. AXS-12 concurrently improved EDS and cataplexy as compared to placebo. Concurrent EDS and cataplexy response was achieved at Week 5 by 57% of patients treated with AXS-12 compared to 33% of placebo patients. Concurrent EDS and cataplexy response was defined as a greater than or equal to30% reduction in inadvertent naps, and a greater than or equal to50% reduction in cataplexy attacks. A decrease in the number of inadvertent naps was experienced by 54% of AXS-12 patients at Week 5 compared to 28% of placebo patients, assessed by the Narcolepsy Symptom Assessment Questionnaire. Improvement on the Epworth Sleepiness Scale was numerically greater for AXS-12 than for placebo, with mean reductions from baseline of 4.7 points for AXS-12 compared to 3.4 points for placebo. A greater than or equal to3-point improvement from baseline on the ESS was achieved by 60% of AXS-12 patients who had a cataplexy response. AXS-12 significantly improved concentration and memory as measured by the Cognitive Function Items of the Functional Outcomes of Sleep Questionnaire at Week 5. AXS-12 concurrently improved cognition and cataplexy as compared to placebo. Concurrent cognitive and cataplexy response was achieved at Week 5 by 41% of patients treated with AXS-12 compared to 17% of placebo patients. Response was defined by an increase in days patients rated their Ability to Concentrate as very good or good, and a greater than or equal to50% reduction in cataplexy attacks. AXS-12 improved narcolepsy overall disease condition, and patient function and quality of life. Clinicians reported a rapid and significant reduction in overall narcolepsy severity for patients treated with AXS-12 compared to placebo at Week 5, with improvements observed as early as Week 1. AXS-12 demonstrated significant improvement in overall patient function and quality of life as measured by the FOSQ-10 total score as compared to placebo at Week 5. Anxiety and depression, known common narcolepsy co-morbidities, was reported by 45% of study participants at baseline, as assessed by the EuroQol. Improvement from baseline in the Anxiety/Depression domain of the EQ-5D-5L was achieved by 55% of patients treated with AXS-12 compared to 32% of placebo patients. AXS-12 was well tolerated in the trial. The most commonly reported adverse events in the AXS-12 arm were dry mouth, nausea, and constipation, which were overall mild to moderate. The rates of discontinuation due to adverse events was low. There were no serious adverse events in the trial.

06:24 EDT ProKidney appoints Ulrich Ernst as EVP, technical operations - ProKidney announced two recent strategic appointments enhancing the leadership team's expertise in clinical operations and technical operations, positioning the Company for completion of its Phase 3 program and future commercialization. Dr. Ulrich Ernst, PhD joins the Company today as Executive Vice President of Technical Operations, and Mr. Lucio Tozzi was appointed Senior Vice President of Global Clinical Operations on January 22, 2024. Both Dr. Ernst and Mr. Tozzi and will be joining the ProKidney Executive Leadership Team. Prior to ProKidney, Dr. Ernst was Senior Vice President of Technical Operations at Iovance Biotherapeutics, COO at Amunix Operating Inc., and Senior Vice President of Manufacturing Operations at Cytovance Biologics. Prior to ProKidney, Mr. Tozzi was Senior Vice President and Head of Clinical Operations at Summit Therapeutics and Rain Oncology, and, prior to that, Vice President of Clinical Operations at Protagonist Therapeutics.

06:20 EDT Sagimet Biosciences expects cash to fund operations for at least next 12 months - Cash, cash equivalents and marketable securities for the year ended December 31, 2023 were $94.9 million, and together with the $104.7 million in net proceeds from the January 2024 public offering, are expected to fund operations for at least the next 12 months based on management's current operating plan.

06:17 EDT AstraZeneca reports Ultomiris approved in U.S. for adults with NMOSD - Ultomiris has been approved in the United States as "the first and only long-acting C5 complement inhibitor" for the treatment of adult patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder, or NMOSD, AstraZeneca announced. Ultomiris is also approved for certain adults with NMOSD in Japan and the European Union. Regulatory reviews are ongoing in additional countries. Marc Dunoyer, Chief Executive Officer, Alexion, said: "Alexion has been at the forefront of innovation in NMOSD, striving to offer patients a future without fear of life-altering or even fatal relapses. Building on the established efficacy of C5 inhibition for people living with AQP4 Ab+ NMOSD, we are proud to deliver a transformative, long-acting treatment option that has the potential to eliminate relapses with a convenient dosing schedule every eight weeks. We are grateful to the NMOSD community for their ongoing collaboration and input, which enables us to advance science for rare diseases."

06:13 EDT Zoom Video launches Zoom Workplace in AWS Marketplace - Zoom announced that Zoom Workplace (ZM) is now available in AWS Marketplace (AMZN), a digital catalog with thousands of software listings from independent software vendors that make it easy to find, test, buy, and deploy software that runs on Amazon Web Services. Now customers can seamlessly purchase Zoom Workplace products -- such as Meetings, Team Chat, Phone, Whiteboard, Spaces - as well as Zoom Contact Center and Revenue Accelerator in AWS Marketplace.

06:12 EDT Alphabet, Apple, Meta to be probed by EU under DMA - The European Commission has opened non-compliance investigations under the Digital Markets Act into Alphabet's (GOOGL) rules on steering in Google Play and self-preferencing on Google Search, Apple's (AAPL) rules on steering in the App Store and the choice screen for Safari and Meta's (META) "pay or consent model". The Commission said it suspects that the measures put in place by these gatekeepers fall short of effective compliance of their obligations under the DMA. In addition, the Commission said it has launched investigatory steps relating to Apple's new fee structure for alternative app stores and Amazon's ranking practices on its marketplace. Finally, the Commission has ordered gatekeepers to retain certain documents to monitor the effective implementation and compliance with their obligations. The Commission has opened proceedings to assess whether the measures implemented by Alphabet and Apple in relation to their obligations pertaining to app stores are in breach of the DMA. The Commission is concerned that Alphabet's and Apple's measures may not be fully compliant as they impose various restrictions and limitations. The Commission has opened proceedings against Alphabet, to determine whether Alphabet's display of Google search results may lead to self-preferencing in relation to Google's vertical search services over similar rival services. Finally, the Commission has opened proceedings against Meta to investigate whether the recently introduced "pay or consent" model for users in the EU complies with Article 5(2) of the DMA which requires gatekeepers to obtain consent from users when they intend to combine or cross-use their personal data across different core platform services. The Commission intends to conclude the proceedings opened today within 12 months. Reference Link

06:10 EDT Century Aluminum selected by DOE to receive $500M investment - Century Aluminum Company was selected by the U.S. Department of Energy Office of Clean Energy Demonstrations to begin award negotiations for up to $500 million in Bipartisan Infrastructure Law and Inflation Reduction Act funding to build a new aluminum smelter as part of the Industrial Demonstrations Program. Century's Green Aluminum Smelter Project is one of 33 projects across more than 20 states to receive funding designed to demonstrate commercial-scale decarbonization solutions needed to move energy-intensive industries toward net-zero while strengthening local economies, creating, and maintaining high-quality jobs, and slashing greenhouse gas emissions. With the help of this funding, Century plans to build the first new U.S. primary aluminum smelter in 45 years. Upon completion, the smelter would double the size of the current U.S. primary aluminum industry. Century expects to build this new smelter at a site within the Ohio/Mississippi River Basins. This project is expected to create more than 1,000 full-time jobs represented by the United Steelworkers and over 5,500 construction jobs. Century plans to collaborate with job training organizations and local technical colleges to recruit and train employees from the local community where the smelter is located.

06:10 EDT Alphabet, Apple, Meta to be probed by EU under DMA

06:08 EDT Zoom Video unveils Zoom Workplace platform - Zoom Video Communications announced Zoom Workplace, its AI-powered, open collaboration platform, and introduced new AI Companion expansions to help reimagine teamwork. Zoom's latest products and features, including new AI Companion features for Zoom Phone and extended capabilities with Ask AI Companion, a refreshed look within the Zoom app, and more, will provide its customers with the all-in-one AI-powered platform they need to power modern work. Zoom also announced customer experience enhancements to Zoom Contact Center, so businesses can strengthen customer relationships and leverage real-time AI-powered insights to improve live agent engagements. "We have seen the positive impact that Zoom AI Companion has had on our business and our customers, transforming how we work by freeing up precious time for collaborative teamwork," said Smita Hashim, chief product officer at Zoom. "Zoom Workplace with AI Companion will help solve real customer problems by bringing the core collaboration solutions into a single AI-powered platform to help improve productivity, efficiency, and the overall workday, all within the Zoom experience users trust and love."

06:05 EDT Matador announces completion of natural gas pipeline connections - Matador Resources announced that Matador and its lenders successfully amended the Company's credit agreement to, among other things, increase the elected commitment from $1.325 billion to $1.5 billion, increase the maximum facility amount from $2.0 billion to $3.5 billion and extend the maturity date by three years to 2029. Matador is also pleased to announce that five new banks joined the credit facility, bringing the total bank group to 19 banks. These new banks are Capital One, N.A., Citizens Bank, N.A., Mizuho Bank, Ltd., The Toronto-Dominion Bank, New York Branch, and Wells Fargo Bank, N.A. Matador also announced the completion of natural gas pipeline connections between Pronto Midstream and San Mateo and between Pronto Midstream and Matador's acreage obtained in the Advance acquisition. These connector pipelines will provide further flow assurance and options for Matador and third-party customer natural gas volumes and should contribute to the resolution of the temporary midstream third-party maintenance issues experienced in the first quarter of 2024.

06:03 EDT LightInTheBox receives noncompliance notification from NYSE - LightInTheBox announced that it has received a letter from the NYSE dated March 12, notifying that the company is "below criteria" due to the average closing price of the company's ADSs being less than $1.00 over a consecutive 30-tradingday period pursuant to Section 802.01C of the NYSE Listed Company Manual.

05:10 EDT Vaalco Energy finalizes agreements in Equatorial Guinea - Vaalco Energy announced that all partners have signed the final documents and the Government of Equatorial Guinea has approved the Joint Operating agreement. or JOA, related to the previously approved Venus-Block P Plan of Development. or POD. The Block P production sharing contract provides for a development and production period of 25 years from the date of approval of the POD.